| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
phase 2 data readout example | PCRX-201 (enekinragene inzadenovec) osteoarthritis (OA) of the knee | Phase 2 | — | Gene Therapies | Musculoskeletal System | ||
phase 2 data readout example | PCRX-201 (enekinragene inzadenovec) osteoarthritis (OA) of the knee | Phase 2 | — | Gene Therapies | Musculoskeletal System | ||
phase 2 data readout example | PCRX-201 (enekinragene inzadenovec) osteoarthritis (OA) of the knee | Phase 2 | — | Gene Therapies | Musculoskeletal System |
Recent Updates
Recently added Catalysts
Pacira BioSciences, Inc.$25.24
+0.87 (+3.57%)
B 63Pipeline Score Undervalued Pharma · Commercial
Market Cap
918.47 M
EPS
0.13
P/E Ratio
186.95 $
Value Trade
5.47 M
SEC Financials
Q1 2026Dilution Risk
Revenue
177.38 M
R&D Expenses
28.07 M
Operating CF
25.68 M
Total Assets
1.21 B
Total Liabilities
554.64 M
Equity
653.89 M
D/E Ratio
12,345
-1.23 %
Week
-5.27 %
1 Month
0.43 %
3 Month
2.59 %
6 Month
-65.11 %
5 Year
233.57 %
All Time
Cash Data
Cash Position
202.18 M
Monthly Burn
-
Runway
12,345 mo
Burn Trend
StableSEC Filing
Apr 30, 2026
Overview
Volume
1.02 M
52 Week Range
18.80 - 27.64
% held by Insiders
4.25 %
% held by Institutions
113.39 %
Enterprise Value
1.13 B
Total Shares
40.48 M
Short %
16.55 %
Float Shares
37.93 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
B63
Pipeline Score $3.4B
Pipeline ValueUndervalued
Valuation Signal13
Drugs Scored12.3x
rNPV / MCap Top 91%
Micro Cap (rank 82 of 905)
Percentile RankPacira BioSciences, Inc. holds a solid B-grade pipeline (63/100), with $8.5B risk-adjusted pipeline value, led by SKY0402 in Postoperative Pain (Phase 3), across $94B in total addressable markets.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SKY0402 Small molecule | Hemorrhoids | Phase 3 | NCT00744848 | 50% | $5.5B | COMPLETED | 204 | - | - | Feb 1, 2009 | - | Aug 6, 2013 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
ZILRETTA | osteoarthritis knee pain | Phase 3 | 2025-07-23 | |||
ZILRETTA | osteoarthritis knee pain | Phase 3 | 2025-07-23 | |||
ZILRETTA | osteoarthritis knee pain | Phase 3 | 2025-07-23 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in PCRX
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Pacira BioSciences, Inc. (PCRX) Analyst Ratings & Price Targets
Symbol
Firm
Rating
Action
Price Target
Upside
date
PCRX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
PCRX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
PCRX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
PCRX Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
PCRX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
PCRXPacira BioSciences Announces Stockholders Have Elected All Three of the Company's Director Nominees at Annual Meeting
Pacira BioSciences has announced that all three of its nominated directors have been elected to the Board during the 2026 Annual Meeting of Stockholders. The preliminary results bolster the company's leadership team, enhancing its commitment to delivering non-opioid pain therapies. CEO Frank D. Lee expressed appreciation for the stockholders' trust as the company aims to execute its strategic '5x30' plan. Final results will be reported in a forthcoming SEC filing, ensuring transparency in corporate governance.
Read more →PCRXPacira BioSciences Highlights Leading Independent Proxy Advisory Firm ISS’ Recommendation to Vote “FOR” All of Pacira’s Director Nominees
Pacira BioSciences has received a positive recommendation from ISS to vote for its director nominees ahead of the 2026 Annual Meeting. The advisory firm noted improvements in Pacira's performance linked to its strategic initiatives and criticized the opposing nominees from DOMA for lacking relevant experience. Pacira encourages stockholders to support its nominees and disregard DOMA's proxy card.
Read more →PCRXPacira BioSciences Highlights Leading Independent Proxy Advisory Firm ISS' Recommendation to Vote "FOR" All of Pacira's Director Nominees
Pacira BioSciences received a positive recommendation from ISS to vote for its director nominees ahead of the 2026 Annual Meeting. ISS highlighted the company's improved performance and proactive governance under its current board. In contrast, ISS criticized DOMA's nominees for lacking relevant experience and presenting an unconvincing case for change. Pacira urges stockholders to support its nominees and disregard DOMA's proxy card.
Read more →PCRXLeading Independent Proxy Advisory Firm Glass Lewis Recommends Stockholders Vote “FOR” All of Pacira’s Director Nominees
Pacira BioSciences received a positive recommendation from Glass Lewis to vote for its director nominees ahead of the 2026 Annual Meeting. The advisory firm highlighted Pacira's strong stockholder returns and the effectiveness of its 5x30 strategy. Glass Lewis also criticized DOMA Perpetual's nominees, questioning their capability to implement a transformative strategic review.
Read more →PCRXPacira BioSciences Reports Real-World Study Showing EXPAREL® Use Was Associated with Reduced Opioid Use and Healthcare Costs in Patients Undergoing Total Shoulder Arthroplasty
Pacira BioSciences announced findings from a real-world study showing that the use of EXPAREL after total shoulder arthroplasty resulted in lower opioid consumption, reduced healthcare costs, and fewer opioid-related adverse events. The study, presented at ISPOR 2026, involved over 6,400 Medicare Advantage patients and highlights the importance of non-opioid pain management strategies amidst rising surgical procedures.
Read more →PCRXPacira BioSciences Mails Letter to Stockholders Reiterating Confidence in the Company’s Strategic Direction and Highly Qualified Nominees
Pacira BioSciences has communicated its confidence in its strategic direction, urging stockholders to vote for its nominated board members ahead of the 2026 Annual Meeting. The company highlighted its significant progress under the 5x30 strategy, which has led to record revenues and stock price appreciation. Additionally, the recent favorable settlement regarding EXPAREL provides a solid foundation for future growth and stability. The communication aims to reassure investors about Pacira's potential and operational strength.
Read more →PCRXPacira BioSciences Sets the Record Straight Regarding DOMA’s Misleading Statements About Pacira’s Intellectual Property Strategy
Pacira BioSciences has issued a statement defending its intellectual property strategy in response to misleading claims by DOMA Perpetual Capital Management. The company asserts the strength of its patent portfolio, especially regarding the EXPAREL franchise, and highlights successful legal outcomes, such as the reexamination of its '495 patent. Pacira encourages stockholders to support its board nominees in light of this controversy. The company aims to continue its expansion strategy while addressing the challenges posed by generic competition.
Read more →PCRXPacira BioSciences Files Investor Presentation Highlighting Successful Execution of its Long-Term Strategy to Drive Value for All Stockholders
Pacira BioSciences is urging stockholders to vote for its nominees ahead of the 2026 Annual Meeting, following the release of an investor presentation that highlights the successful execution of its 5x30 strategy. The company achieved record revenues and strong sales growth in its pain management products EXPAREL, ZILRETTA, and iovera° during 2025 and into 2026. Pacira has also recently settled patent litigation favorably, ensuring exclusivity for its key product until 2030. The board of directors is emphasizing the importance of their experienced slate for sustaining long-term growth.
Read more →PCRXPacira BioSciences Sends Letter to Stockholders Reiterating Superior Qualifications of its Board Nominees
Pacira BioSciences has sent a letter to stockholders urging them to vote for its board nominees ahead of the 2026 Annual Meeting. The company emphasizes the qualifications and experience of its nominees, contrasting them with those proposed by DOMA Perpetual Capital Management, which Pacira claims lack the necessary expertise. The letter highlights the importance of maintaining a strong board to support its growth strategy.
Read more →PCRXPacira BioSciences to Participate in Fireside Chats at Three Upcoming Healthcare Conferences
Pacira BioSciences, Inc. announced its participation in three upcoming healthcare conferences, including the RBC Capital Markets Global Healthcare Conference and the Jefferies Global Healthcare Conference. These events will feature analyst-led fireside chats, highlighting the company's commitment to innovative, non-opioid pain therapies. Live audio of the events will be accessible on their website.
Read more →PCRXPacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Pacira BioSciences, Inc. granted inducement awards to ten new employees under its Amended and Restated 2014 Inducement Plan. The awards, consisting of stock options and restricted stock units, were approved under Nasdaq Listing Rule 5635(c)(4) without stockholder approval. This strategic move aims to attract and retain talent in the company's ongoing efforts to drive growth, particularly in innovative, non-opioid pain therapies. Pacira's current portfolio includes several commercial-stage treatments and promising clinical-stage assets.
Read more →PCRXPacira BioSciences Mails Letter to Stockholders
Pacira BioSciences announced the mailing of a letter to stockholders ahead of its 2026 Annual Meeting, urging them to vote for its nominated board members. The letter highlights the company's successful execution of its 5x30 strategy, achieving significant milestones in patient treatment and product revenue growth. Pacira's first quarter 2026 financial results show strong sales and a positive outlook for future growth, driven by innovative therapies and a robust marketing strategy. The CEO emphasized the importance of maintaining experienced leadership to safeguard the company's trajectory.
Read more →PCRXPacira BioSciences Reports First Quarter 2026 Financial Results
Pacira BioSciences reported a revenue increase of 5% to $177 million for Q1 2026, fueled by growth in the EXPAREL commercial portfolio. The company completed patient enrollment in a Phase 3 registration study of ZILRETTA for shoulder osteoarthritis pain, with topline data anticipated by the end of the year. Despite the growth, GAAP net income fell compared to the previous year, reflecting higher operating expenses. For 2026, Pacira reiterated its revenue guidance and expects increased sales from its product lines.
Read more →PCRXPacira BioSciences Files Definitive Proxy Materials and Mails Letter to Shareholders
Pacira BioSciences has filed definitive proxy materials and is urging stockholders to vote for its three board nominees ahead of the Annual Meeting on June 9, 2026. The company emphasizes its strong position and growth trajectory, highlighting a robust increase in stock price and a successful 5x30 strategy aimed at long-term value creation. Conversely, Pacira opposes the election of nominees proposed by DOMA, stating they lack the requisite industry experience and could undermine the strategic direction of the company.
Read more →PCRXReal-World Data on EXPAREL® Shows Reduced Opioid Use and Lower Total Medical Costs in Medicare Patients Undergoing Total Hip Arthroplasty
Pacira BioSciences presented findings from a real-world study showing that EXPAREL (bupivacaine liposome injectable suspension) significantly reduces opioid use and lowers total medical costs for Medicare patients undergoing outpatient total hip arthroplasty. The study demonstrated lower healthcare resource utilization and fewer opioid-related adverse events among patients administered EXPAREL compared to standard care options.
Read more →PCRXPacira to Report First Quarter 2026 Financial Results on Thursday April 30, 2026
Pacira BioSciences, Inc. will report its first quarter 2026 financial results on April 30, 2026, after U.S. market close. A live conference call and webcast will follow at 4:30 p.m. ET, allowing for participant questions. The company focuses on innovative, non-opioid pain therapies and has several treatments and clinical-stage assets.
Read more →PCRXPacira Presents Real-World Data on EXPAREL® Showing Lower Total Healthcare Costs in Outpatient Total Hip and Knee Arthroplasty Procedures
Pacira BioSciences presented real-world data at the AMCP Annual Meeting, demonstrating that EXPAREL® (bupivacaine liposome injectable suspension) is associated with lower total healthcare costs and reduced opioid use in outpatient total hip and knee arthroplasty procedures. The findings indicate significant cost savings, particularly for patients with lower back pain, reinforcing the economic value of non-opioid pain management solutions.
Read more →PCRXPacira BioSciences to Participate in Fireside Chat at the 25th Annual Needham Virtual Healthcare Conference
Pacira BioSciences, Inc. will participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on April 15, 2026. The event will be accessible via the company's website, with a replay available for two weeks. Additionally, Pacira announced inducement grants to new employees as part of its employment strategy, including stock options and restricted stock units.
Read more →PCRXPacira BioSciences to Present Real-World Data on EXPAREL® Showing Reduced Cost of Care at Orthopaedic Research Society 2026 Annual Meeting
Pacira BioSciences announced findings from two studies demonstrating that EXPAREL® (bupivacaine liposome injectable suspension) significantly reduces the total cost of care in total knee arthroplasty and spinal fusion procedures. The data, which will be presented at the Orthopaedic Research Society 2026 Annual Meeting, highlights lower costs and healthcare resource utilization compared to traditional pain management options. The studies suggest that EXPAREL can improve patient outcomes while reducing economic barriers.
Read more →PCRXPacira BioSciences Reaffirms Commitment to Shareholder Value Creation
Pacira BioSciences has reaffirmed its commitment to shareholder value amidst a nomination of director candidates by DOMA Perpetual Capital Management. The company has made significant progress toward its goals, treating 2.5 million patients in 2025 and achieving notable financial targets. Pacira's Board expressed confidence in their long-term strategic plan, which includes advancing innovative therapies and maintaining shareholder communications. However, the situation with DOMA highlights potential dissent among shareholders regarding company governance.
Read more →PCRXPacira BioSciences to Participate in Fireside Chat at the Barclays 28th Annual Global Healthcare Conference
Pacira BioSciences will participate in a fireside chat at the Barclays 28th Annual Global Healthcare Conference on March 11, 2026. The event will be accessible via live audio on the company's website, with a replay available for two weeks. Pacira is known for its innovative non-opioid pain therapies and has a pipeline of clinical-stage assets.
Read more →PCRXPacira BioSciences Presents Two Real-World Studies from Its Innovations in Genicular Outcomes Registry (IGOR)
Pacira BioSciences presented two studies at the AAOS 2026 Annual Meeting, showcasing the effectiveness of EXPAREL in managing pain post-total knee arthroplasty and the long-term benefits of iovera for knee osteoarthritis. The studies highlighted significant improvements in pain management and functional outcomes, emphasizing the potential of these treatments in enhancing patient recovery.
Read more →PCRXPacira BioSciences Reports Fourth Quarter and Full-Year 2025 Financial Results
Pacira BioSciences reported strong financial results for Q4 and the full year of 2025, driven by record EXPAREL sales. The company achieved revenue of $726 million for the year, marking a 4% increase, and reported the highest gross margins in its history. Operationally, they expanded their board and established a strategic partnership with LG Chem to enhance market access in Asia. However, rising operating costs and a decrease in non-GAAP net income highlight ongoing challenges.
Read more →PCRXPacira Highlights New NOPAIN Act Survey Data Conducted by Voices for Non-Opioid Choices
Pacira BioSciences has highlighted new survey data from the Voices for Non-Opioid Choices coalition regarding the NOPAIN Act's impact. The survey, which included nearly 750 healthcare professionals, indicates that the Act is effectively increasing access to non-opioid pain management for Medicare patients. Pacira's CEO emphasized the importance of this policy in reducing opioid reliance post-surgery.
Read more →PCRXPacira to Report 2025 Financial Results on Thursday February 26, 2026
Pacira BioSciences, Inc. has announced that it will report its fourth quarter and year-end financial results for 2025 on February 26, 2026. The report will be made available after the U.S. markets close, followed by a live conference call at 4:30 p.m. ET. The company focuses on innovative, non-opioid pain management therapies and has various products in its portfolio, including EXPAREL®, ZILRETTA®, and the iovera® device. Additionally, Pacira is developing clinical assets aimed at treating musculoskeletal pain.
Read more →PCRXPacira BioSciences Appoints Samit Hirawat, M.D., to Board of Directors
Pacira BioSciences has appointed Dr. Samit Hirawat to its Board of Directors, expanding the board to 10 members. Dr. Hirawat, a veteran in clinical development, previously held senior roles at Bristol Myers Squibb and Novartis. His expertise is expected to enhance Pacira's commitment to innovative, non-opioid pain management solutions.
Read more →PCRXPacira Announces Agreement with LG Chem to Make EXPAREL® Available in Select Asian-Pacific Markets
Pacira BioSciences has entered into an exclusive distribution agreement with LG Chem to commercialize EXPAREL in select Asian-Pacific markets. This partnership aims to enhance patient access to opioid-sparing pain management solutions. LG Chem will handle regulatory approvals and marketing authorizations in South Korea and Thailand, while Pacira will manufacture the product.
Read more →PCRXPacira Reports Preliminary Unaudited Fourth Quarter and Full-Year 2025 Revenues
Pacira BioSciences reported preliminary unaudited revenues of $726.4 million for 2025, reflecting a 3.5% increase from 2024. The company highlighted a 7% growth in EXPAREL sales, marking its strongest fourth quarter in three years. Additionally, Pacira repurchased 2 million shares in Q4, demonstrating confidence in its future. Full financial results will be disclosed in Q1 2026.
Read more →PCRXPacira BioSciences to Present at the 44th Annual J.P. Morgan Healthcare Conferences
Pacira BioSciences, Inc. will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026. The company focuses on innovative, non-opioid pain therapies and has several commercial-stage products. The event will be accessible live and will include a replay for two weeks after the presentation.
Read more →PCRXPacira Biosciences Joins PROBE Consortium to Transform Osteoarthritis Research and Care
Pacira Biosciences has announced its membership in the PROBE Consortium, aiming to enhance osteoarthritis research and patient outcomes. This collaboration will utilize data from over 70 million individuals to address challenges in OA treatment and care. The initiative seeks to develop new trial endpoints and tools that improve shared decision-making between patients and healthcare providers. Pacira will also contribute findings from its ongoing ASCEND study, focusing on its investigational therapy PCRX-201.
Read more →PCRXPacira BioSciences Announces Results From 12-Month Pilot Study Demonstrating Favorable Safety and Significant Improvements in Pain With iovera° Compared to Radiofrequency Ablation in Chronic Low Back Pain
Pacira BioSciences announced positive results from a 12-month pilot study comparing iovera° cryoneurolysis to radiofrequency ablation for chronic low back pain. The study, involving 30 patients, showed significant improvements in pain relief and functional outcomes without adverse events. The findings support the use of iovera° as a non-opioid alternative for pain management.
Read more →PCRXPacira BioSciences Files EXPAREL Patent Infringement Lawsuits Against The WhiteOak Group and Qilu Pharmaceutical
Pacira BioSciences has initiated patent infringement lawsuits against The WhiteOak Group and Qilu Pharmaceutical regarding their attempts to develop generic versions of EXPAREL, triggering a 30-month stay for FDA approvals under the Hatch Waxman Act. The company's litigation efforts aim to prevent the manufacturing and market entry of these generics, safeguarding its patent rights which extend until 2044. Pacira expresses confidence in its patent portfolio and plans to vigorously defend its intellectual property against these competitors.
Read more →PCRXPacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences
Pacira BioSciences, Inc. will participate in two upcoming healthcare conferences, featuring an analyst-led fireside chat. The events will be accessible via live audio on the company's website, with replays available for two weeks. Pacira continues to focus on innovative, non-opioid pain therapies, including its commercial products and ongoing development of novel treatments.
Read more →PCRXPacira BioSciences Reports Third Quarter 2025 Financial Results; Increases Full-year Gross Margin Guidance
Pacira BioSciences reported a 6% revenue increase in Q3 2025, driven by a 9% rise in EXPAREL sales. The company updated its financial guidance for the year, highlighting its 5x30 growth strategy and recent advancements in its product pipeline, including the in-licensing of AMT-143. A conference call is scheduled to discuss these results and future plans.
Read more →PCRXPacira BioSciences Concludes Patient Enrollment in Part A of Phase 2 Study Evaluating Safety and Efficacy of PCRX-201 for the Treatment of Osteoarthritis of the Knee
Pacira BioSciences has completed patient enrollment in Part A of its Phase 2 ASCEND study for PCRX-201, a gene therapy targeting osteoarthritis of the knee. The study aims to evaluate the safety and efficacy of the treatment, with topline results expected by the end of 2026. PCRX-201 is designed to enhance IL-1Ra production to combat inflammation and pain.
Read more →PCRXPacira BioSciences Enters Exclusive License Agreement with AmacaThera for its Novel Long-acting Analgesic for Postsurgical Pain Control
Pacira BioSciences has entered an exclusive license agreement with AmacaThera for AMT-143, a long-acting formulation of ropivacaine aimed at postsurgical pain control. The Phase 2 program for AMT-143 is expected to begin in 2026. This collaboration is part of Pacira's strategy to expand its pipeline and enhance its offerings in non-opioid pain management.
Read more →PCRXPacira to Report Third Quarter 2025 Financial Results on Thursday November 6, 2025
Pacira BioSciences, Inc. will report its third quarter financial results on November 6, 2025, after the U.S. markets close. Following the release, a live conference call and webcast will be held at 4:30 p.m. ET. The company emphasizes its commitment to non-opioid pain therapies, showcasing its innovative product offerings.
Read more →PCRXPacira BioSciences Presents Updated Three-Year Data Demonstrating Sustained Efficacy and Safety of PCRX-201 Gene Therapy for Patients with Moderate-to-Severe Osteoarthritis of the Knee
Pacira BioSciences has presented updated three-year data from its Phase 1 trial of PCRX-201, a gene therapy for knee osteoarthritis. The results indicate sustained efficacy and safety, with improvements in pain, stiffness, and function lasting up to 156 weeks post-treatment. The therapy is well-tolerated and shows promise for long-term relief, potentially transforming treatment approaches for osteoarthritis.
Read more →PCRXPacira BioSciences Notified of Abbreviated New Drug Application Filing from Qilu Pharmaceutical (Hainan) Co., Ltd. for EXPAREL®
Pacira BioSciences has received a Paragraph IV Certification Notice from Qilu Pharmaceutical, which has filed an ANDA for a generic version of EXPAREL. Qilu claims that 18 patents related to EXPAREL are invalid or unenforceable. Pacira plans to assert its intellectual property rights and has 45 days to respond, which could lead to a lawsuit that would delay Qilu's FDA approval.
Read more →PCRXPacira BioSciences to Present New Data from Three Real-World Studies with EXPAREL®
Pacira BioSciences announced that new real-world evidence regarding the effectiveness and economic benefits of EXPAREL will be presented at the AMCP Nexus 2025 Annual Meeting. The data includes findings from the Innovations in Genicular Outcomes Registry, aimed at enhancing postsurgical pain management and reducing opioid dependency. The meeting will take place from October 27 to 30 in National Harbor, Maryland.
Read more →PCRXPacira BioSciences Notified of Abbreviated New Drug Application Filing from The WhiteOak Group for EXPAREL®
Pacira BioSciences has received a Paragraph IV Certification Notice from The WhiteOak Group, which has filed an Abbreviated New Drug Application for a generic version of EXPAREL. The notice claims that 19 patents related to EXPAREL are invalid or unenforceable. Pacira plans to assert its intellectual property rights and has 45 days to initiate legal action, which could delay FDA approval of WhiteOak's application.
Read more →PCRXPacira BioSciences to Present 3-Year Data Demonstrating Sustained Pain and Function Improvements in Knee Osteoarthritis with Investigational PCRX-201 Gene Therapy
Pacira BioSciences, Inc. announced the presentation of new three-year data on PCRX-201, a novel gene therapy for knee osteoarthritis, at the ACR Convergence 2025. The therapy has demonstrated sustained pain relief and functional improvements in patients, as well as a favorable safety profile. Additionally, PCRX-201 has gained RMAT and ATMP designations from regulatory agencies, highlighting its potential in treatment. The company continues to advance its gene therapy research and development efforts through acquisitions and innovative approaches.
Read more →PCRXPacira BioSciences Reports Second Quarter 2025 Financial Results
Pacira BioSciences reported its financial results for Q2 2025, indicating a total revenue of $181.1 million, an increase from the previous year. The company experienced a net loss of $4.8 million, despite achieving a non-GAAP net income of $36.0 million. Key milestones include surpassing 50% enrollment in a Phase 2 study for osteoarthritis and entering a strategic partnership to enhance the promotion of ZILRETTA. Although the total revenue guidance was slightly narrowed, adjustments in gross margin projections suggest a more favorable operational outlook.
Read more →PCRXPacira to Report Second Quarter 2025 Financial Results on Tuesday August 5, 2025
Pacira BioSciences, Inc. announced that it will report its second quarter financial results on August 5, 2025, after the close of U.S. markets. A live conference call and webcast will follow at 4:30 p.m. ET, allowing participants to engage in a Q&A session. The company focuses on innovative, non-opioid pain therapies, including its commercial treatments EXPAREL, ZILRETTA, and iovera, as well as the development of PCRX-201, a novel gene therapy.
Read more →PCRXPacira BioSciences Announces Strategic Collaboration to Significantly Expand ZILRETTA Promotional Efforts
Pacira BioSciences announced a strategic collaboration with Johnson & Johnson MedTech to enhance the promotion of ZILRETTA, their extended-release treatment for osteoarthritis knee pain. This partnership is expected to expand ZILRETTA's market reach through a specialized sales force, increasing patient access and facilitating individualized pain management across various physician specialties. The deal aligns with Pacira's 5x30 strategy, aiming to boost growth and improve patient experiences with non-opioid therapies. This collaboration could lead to greater adoption and use of ZILRETTA in managing osteoarthritis-related knee pain in the U.S.
Read more →PCRXPacira BioSciences Debuts Inspiring New Film Highlighting One Patient’s Journey to Pain Relief and Innovation in Care at BIO 2025
Pacira BioSciences has premiered a new film titled 'The Next Frontier: Mark & Leah's Story' at the BIO Convention 2025, which highlights the journey of Mark Allen and his wife Leah as they transition from opioid dependence to effective non-opioid pain management solutions. The film emphasizes the transformative impact of alternative therapies on their lives, allowing them to enjoy their family and life without pain. This initiative seeks to raise awareness about non-opioid options amidst the ongoing opioid crisis, showcasing Pacira's commitment to patient-centered approaches in pain management.
Read more →PCRXPACIRA ALERT: Bragar Eagel & Squire, P.C. is Investigating Pacira BioSciences, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. is investigating Pacira BioSciences, Inc. due to a class action complaint alleging breaches of fiduciary duty by the board of directors. This follows a significant disclosure regarding the invalidity of Pacira's key patent related to its revenue-generating product, Exparel. Consequently, the company's stock price suffered a dramatic decline exceeding 47% in one day. The investigation aims to protect long-term shareholders and assess the implications of these legal challenges.
Read more →PCRXPacira BioSciences Unveils Three-Year Clinical Data Following a Single Local Administration of Investigational Gene Therapy, PCRX-201, in Patients with Moderate-to-Severe Osteoarthritis of the Knee
Pacira BioSciences has released promising three-year clinical data from its Phase 1 trial of PCRX-201, a gene therapy for osteoarthritis of the knee. The therapy showed sustained improvements in pain, stiffness, and function among patients, highlighting its potential to transform treatment approaches. Notably, no serious adverse events were linked to the treatment, and the therapy received both RMAT and ATMP designations from respective regulatory agencies. Ongoing investigations into a Phase 2 study, the ASCEND study, aim to further evaluate the efficacy of PCRX-201.
Read more →PCRXPacira BioSciences Presents New Data on the Effects of Clinical Immunogenicity on Locally Administered PCRX-201 in Patients with Moderate to Severe Osteoarthritis of the Knee
Pacira BioSciences has announced preliminary data indicating that the gene therapy candidate PCRX-201 exhibits no significant impact from pre-existing or treatment-induced anti-Ad5 neutralizing antibodies on its safety or efficacy. This data, which will be featured at the ASGCT Annual Meeting, suggests that PCRX-201 can provide sustained relief in knee pain, stiffness, and function for patients with osteoarthritis. The therapy's innovative design aims to enhance pain management and improve the quality of life for millions affected by the condition.
Read more →PCRXPacira BioSciences Reports First Quarter 2025 Financial Results
Pacira BioSciences reported its financial results for the first quarter of 2025, highlighting total revenues of $168.9 million, showing a modest growth compared to the same period last year. The successful settlement of a patent litigation for EXPAREL allows for exclusivity until 2039, greatly reinforcing their market position. However, there was a notable decrease in GAAP net income and cash flow from operations. The company continues to advance its 5x30 strategy with ongoing product development and a significant stock buyback initiative.
Read more →PCRXPacira BioSciences to Present 3-Year Safety and Efficacy Data of PCRX-201 Following Single Intra-Articular Injection for Moderate-to-Severe Knee Osteoarthritis
Pacira BioSciences, Inc. announced the upcoming presentation of new 3-year safety and efficacy data for its gene therapy candidate PCRX-201 at the 2025 EULAR Annual Congress. The data suggests that a single intra-articular injection of PCRX-201 is safe and provides sustained clinical benefits for patients suffering from moderate-to-severe knee osteoarthritis. This therapy features an innovative adenovirus vector design and has received significant regulatory designations, underscoring its promise in treating this prevalent condition.
Read more →PCRXPacira BioSciences to Present New Data on Clinical Immunogenicity of Intra-Articular PCRX-201 and Its Implications for Dosing Strategy in Knee Osteoarthritis
Pacira BioSciences, Inc. has announced an upcoming presentation of new data regarding their gene therapy candidate, PCRX-201, for knee osteoarthritis. The findings from a Phase 1 study will be presented at the American Society of Gene and Cell Therapy annual meeting on May 15. The data focuses on the impact of neutralizing antibodies on the therapy's efficacy and safety. Given encouraging Phase 1 results, Pacira is advancing to a Phase 2 study of PCRX-201 to treat knee osteoarthritis.
Read more →PCRXPacira to Report First Quarter 2025 Financial Results on Thursday May 8, 2025
Pacira BioSciences, Inc. is set to release its financial results for the first quarter of 2025 on May 8, 2025, after the U.S. market closes. Following the announcement, a live conference call and webcast will take place at 4:30 p.m. ET, allowing participants to engage in a question and answer session. Pacira is recognized for its commitment to innovative, non-opioid treatments, including three commercial-stage therapies and a novel gene therapy currently in development.
Read more →PCRXPacira BioSciences Announces Two-Year Efficacy Data Following a Single Local Administration of PCRX-201 in Patients with Mild to Severe Osteoarthritis of the Knee
Pacira BioSciences has announced that its gene therapy candidate PCRX-201 showed effective trial results in treating knee osteoarthritis. The study, presented at the OARSI World Congress, highlighted that patients maintained significant improvements in pain and function for up to two years following a single injection. No serious adverse events related to the treatment were reported, although mild to moderate joint effusions were noted in some patients. The results signify a promising advancement in delivering long-lasting relief for those suffering from this chronic condition.
Read more →PCRXPacira BioSciences to Present 104-Week Efficacy Data Following a Single Local Administration of PCRX-201 for Patients with Mild to Severe Osteoarthritis of the Knee
Pacira BioSciences will present new 104-week efficacy data for its gene therapy candidate PCRX-201 at the OARSI World Congress, showcasing improvements in knee osteoarthritis. This therapy has shown sustained benefits in pain and functionality in a previous Phase 1 study. The drug has also received both RMAT and ATMP regulatory designations, highlighting its innovative approach. Ongoing Phase 2 dosing further supports its potential in treating patients with knee osteoarthritis.
Read more →PCRXPacira BioSciences Reaffirms Commitment to Enhancing Value for All Shareholders
Pacira BioSciences, Inc. has reaffirmed its commitment to enhancing shareholder value with a $300 million share repurchase authorization. The company is focused on executing its 5x30 strategic plan, which aims to treat over 3 million patients annually and achieve significant revenue growth. Additionally, Pacira intends to improve gross margins and increase its clinical pipeline with new programs. CEO Frank D. Lee expressed confidence in the company's growth strategies and long-term vision, particularly with the exclusivity of EXPAREL extending to 2039.
Read more →PCRXPacira BioSciences Announces Settlement of U.S. Patent Litigation for EXPAREL
Pacira BioSciences, Inc. announced a settlement of patent litigations concerning its product EXPAREL with Fresenius Kabi USA and other parties. The agreement permits Fresenius to market limited quantities of a generic version of EXPAREL starting in 2030, with no volume restrictions from 2039. The settlement aims to clarify the exclusivity of Pacira's patents and allows the company to concentrate on its growth strategies, especially in non-opioid pain management therapies. Pacira executives expressed confidence in the strength of their intellectual property portfolio and the resolution of the litigation.
Read more →PCRXPacira BioSciences Announces First Patient Dosed in Phase 2 Study Evaluating Safety and Efficacy of PCRX-201 for the Treatment of Osteoarthritis of the Knee
Pacira BioSciences announced that the first patient has been dosed in the Phase 2 ASCEND study evaluating PCRX-201 for knee osteoarthritis. This gene therapy, utilizing a proprietary adenovirus vector, aims to enhance the production of IL-1Ra, an anti-inflammatory protein. The study will include approximately 135 patients and focus on safety and efficacy, with topline results expected by late 2026. The initial Phase 1 study indicated promising results, showing significant pain relief for up to two years after treatment.
Read more →PCRXPacira BioSciences to Participate in Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference
Pacira BioSciences, Inc. announced its participation in an analyst-led fireside chat at the 24th Annual Needham Virtual Healthcare Conference scheduled for April 7, 2025. The event will be accessible live via the company’s investor website, with a replay available for two weeks afterward. Pacira is recognized for its non-opioid pain therapy innovations and is advancing its novel gene therapy, PCRX-201, to address widespread conditions like osteoarthritis.
Read more →PCRXPacira BioSciences Confirms Receipt of Director Nominations from DOMA Perpetual
Pacira BioSciences, Inc. has confirmed the nomination of three candidates from DOMA Perpetual Capital Management for election to its Board of Directors at the 2025 Annual Meeting of Stockholders. The company emphasizes its commitment to enhancing shareholder value and is currently reviewing these nominations. The formal recommendation regarding these candidates will be made in the forthcoming definitive proxy statement. Shareholders do not need to take any action at this time regarding the nominations.
Read more →PCRXPacira BioSciences, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before March 14, 2025 to Discuss Your Rights – PCRX
Pacira BioSciences, Inc. is facing a class action securities lawsuit following a significant loss in stock value due to the invalidation of its key patent. Allegations of securities fraud encompass a period from August 2, 2023, to August 8, 2024, coinciding with a major patent infringement ruling. The patent in question, which contributes to approximately 80% of the company's revenue, was deemed not valid, raising concerns about the company's future and the potential for more generic competition. Shareholders are encouraged to respond before March 14, 2025, to protect their rights.
Read more →PCRXPacira BioSciences, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses; March 14, 2025 Deadline to file Lead Plaintiff Motion
Pacira BioSciences, Inc. is facing a class action lawsuit following a ruling that invalidated its key patent, which is crucial for its main product, Exparel. The ruling suggests that eVenus did not infringe on Pacira's patent rights, leading to worries about potential challenges to the validity of other patents held by the company. Following this news, Pacira's stock experienced a significant decline of over 47% in just one day. Investors are encouraged to contact Portnoy Law Firm for assistance in recovering losses related to their investments in Pacira.
Read more →PCRXPACIRA BIOSCIENCES SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Pacira BioSciences, Inc. - PCRX
ClaimsFiler is reminding investors of Pacira BioSciences, Inc. that the lead plaintiff deadline in a securities class action lawsuit is approaching on March 14, 2025. The lawsuit arises from allegations that the company and its executives failed to disclose crucial information during the Class Period from August 2, 2023, to August 8, 2024. Following the company's patent infringement case loss regarding its Exparel product, Pacira's stock price fell sharply, leading to substantial investor losses. The case is currently pending in the United States District Court for the District of New Jersey.
Read more →PCRXPACIRA BIOSCIENCES SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Pacira BioSciences, Inc. - PCRX
Pacira BioSciences, Inc. is under legal scrutiny as Kahn Swick & Foti, LLC announced a class action lawsuit for investors who incurred losses exceeding $100,000 between August 2, 2023, and August 8, 2024. The lawsuit, pending in the U.S. District Court for New Jersey, claims that the company and some executives failed to disclose important information, violating federal securities laws. Following a patent infringement ruling against its Exparel product, which constitutes 80% of its revenue, shares plummeted by more than 47%, raising serious concerns for shareholders.
Read more →PCRXPacira BioSciences Reports Fourth Quarter and Full-Year 2024 Financial Results
Pacira BioSciences, Inc. reported financial results for the fourth quarter and full year of 2024, highlighting record revenues of $701 million but also a full-year GAAP net loss of $100 million. The company announced its 5x30 growth strategy aiming to enhance its position as a leader in non-opioid pain therapies. Key highlights include FDA clearance for a new chronic pain management device and the acquisition of GQ Bio to bolster its innovative pipeline. Despite challenges with decreased adjusted EBITDA and rising operating expenses, the firm remains optimistic about its growth trajectory.
Read more →PCRXPacira BioSciences Acquires Remaining Equity Stake of GQ Bio
Pacira BioSciences has acquired the remaining 81% equity stake in GQ Bio Therapeutics for approximately $32 million. This acquisition is expected to strengthen Pacira's capabilities in genetic medicines for prevalent musculoskeletal diseases. GQ Bio's high-capacity adenovirus platform will allow for more efficient gene delivery and provide access to a preclinical portfolio. The deal eliminates future milestone payment obligations, providing financial benefits to Pacira and facilitating its transition into a more innovative biopharmaceutical organization.
Read more →PCRXPacira BioSciences to Participate in Fireside Chat at Two Healthcare Conferences in March
Pacira BioSciences, Inc. (Nasdaq: PCRX) will participate in two upcoming healthcare conferences. The Raymond James Annual Institutional Investors Conference on March 5 and Barclays Global Healthcare Conference on March 12 will feature analyst-led fireside chats. Live audio of these events will be accessible via the company’s investor website, with replays available for two weeks post-event. Pacira focuses on delivering innovative, non-opioid pain therapies and is advancing various treatment options.
Read more →PCRXPacira BioSciences, Inc. Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm for More Information – PCRX
Pacira BioSciences, Inc. is facing a securities law class action lawsuit following the invalidation of its critical patent for Exparel. This patent, which accounts for approximately 80% of the company's revenue, was deemed invalid in court, leading to a significant drop in stock price from $22.36 to $11.70 after the announcement. The lawsuit, initiated by shareholders who purchased shares during the specified class period, highlights concerns over the company's patent validity and potential for increased litigation costs. Shareholders are urged to register to participate in the class action by March 14, 2025.
Read more →PCRXPacira to Report 2024 Financial Results on Thursday February 27, 2025
Pacira BioSciences, Inc. will report its 2024 financial results after the close of U.S. markets on February 27, 2025. A live conference call and webcast will follow at 4:30 p.m. ET, allowing participants to engage in a question and answer session. The company is known for its innovative non-opioid pain therapies, including three commercial-stage products aimed at improving patient outcomes. More information can be found on the company's website.
Read more →PCRXPACIRA BIOSCIENCES SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Pacira BioSciences, Inc. – PCRX
Kahn Swick & Foti, LLC has issued a reminder for investors in Pacira BioSciences, Inc. regarding the deadline to file lead plaintiff applications in a securities class action lawsuit. This lawsuit, arising from the company's failure to disclose material information during the class period, follows a recent court ruling that invalidated a key patent related to Pacira's Exparel product, causing a significant drop in its share price. Investors who purchased securities between August 2, 2023, and August 8, 2024, are encouraged to consider their legal rights before the March 14, 2025, deadline.
Read more →PCRXPacira Announces Updates to Board of Directors
Pacira BioSciences, Inc. announced the appointment of Laura Brege as Chair of the Board of Directors, succeeding Paul J. Hastings and Andreas Wicki, PhD, who have retired. This change is part of an ongoing transformation for the Board, which now includes a majority of independent directors with significant industry expertise. Laura Brege’s extensive experience in pharmaceutical management will support Pacira's strategic 5x30 growth plan focused on innovative non-opioid pain therapies. The company emphasized its commitment to improving patient care outcomes while continuing to drive innovation.
Read more →PCRXPacira BioSciences Strengthens Executive Leadership Team with Two Key Appointments
Pacira BioSciences has announced the appointments of Brendan Teehan as Chief Commercial Officer and Krys Corbett as Chief Business Officer. These additions to the executive team are anticipated to support the company's 5x30 strategy aimed at transforming Pacira into an innovative biopharmaceutical organization. Teehan and Corbett bring extensive experience from their previous roles in leading pharmaceutical firms, which could enhance Pacira's market presence as it focuses on advancing its pipeline of non-opioid pain therapies.
Read more →PCRXPacira Announces New Five-Year Objectives to Accelerate Transition into an Innovative Biopharmaceutical Organization
Pacira BioSciences has unveiled a five-year plan aiming to accelerate its transition into a leading biopharmaceutical organization focused on non-opioid pain therapies. The company targets significant growth with objectives that include treating over three million patients annually and achieving a double-digit growth rate in product revenue. Preliminary revenue figures for 2024 indicate a positive trend, with increased net product sales for key offerings. Pacira's leadership is optimistic about leveraging its commercial portfolio and expanding its pipeline to meet unmet patient needs in musculoskeletal pain.
Read more →PCRXPacira BioSciences Receives FDA 510k Clearance for New iovera SmartTip to Manage Chronic Low Back Pain via Long-lasting Medial Branch Nerve Block
Pacira BioSciences has been granted FDA 510(k) clearance for a new iovera SmartTip that allows for treating chronic low back pain by accessing deeper medial branch nerves. The iovera system uses cryoneurolysis to relieve pain without drugs, with effects expected to last for months. Clinical studies demonstrate significant advantages over traditional treatments, including earlier pain relief and higher patient satisfaction. This advancement aims to address the widespread chronic back pain issue in the U.S.
Read more →PCRXPacira BioSciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Pacira BioSciences, Inc. (NASDAQ: PCRX) has announced its participation in the upcoming 43rd Annual J.P. Morgan Healthcare Conference scheduled for January 15, 2025. The company aims to showcase its innovative non-opioid therapies during the presentation. Attendees can access the live audio online, with a replay available for two weeks post-event. Pacira is recognized for its commercial-stage products targeting pain management, including EXPAREL® and ZILRETTA®.
Read more →PCRXPacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Pacira BioSciences, Inc. announced the granting of inducement awards to four new employees as part of their Amended and Restated 2014 Inducement Plan. Under Nasdaq Listing Rule 5635(c)(4), the approval was made by the Compensation Committee of the Board of Directors. The awards consist of stock options to purchase a total of 19,800 shares and restricted stock units for 23,600 shares, intended to incentivize new talent to join the company.
Read more →PCRXPacira Awarded New U.S. Patent Covering EXPAREL Composition
Pacira BioSciences, Inc. announced the issuance of U.S. Patent No. 12,156,940, which protects the composition of its innovative pain management product, EXPAREL. This new patent extends the intellectual property protection of EXPAREL until 2044, affirming the company's commitment to innovation and market leadership in non-opioid therapies. Additionally, the company plans to pursue legal action against entities allegedly infringing on its patents, indicating a proactive approach to safeguarding its intellectual property. Pacira's strategic focus on expanding its patent portfolio is expected to enhance its competitive position in the biopharma industry.
Read more →PCRXPacira Announces 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the Knee
Pacira BioSciences announced positive results from a phase 1 trial of PCRX-201, a gene therapy for moderate to severe osteoarthritis of the knee. The study showed sustained improvements in pain, stiffness, and function for up to 104 weeks following treatment, with a notable safety profile. A poster presentation at the upcoming ACR Convergence meeting will highlight these findings. Plans for a phase 2 study in 2025 are underway, building on the encouraging data and the previous RMAT designation from the FDA.
Read more →PCRXPacira BioSciences Reports Third Quarter 2024 Financial Results
Pacira BioSciences reported its financial results for Q3 2024, showing total revenues of $168.6 million, representing an increase from the previous year. Despite solid sales in its product lineup, the company experienced a significant net loss of $143.5 million, largely due to a goodwill impairment. Looking ahead, Pacira aims to grow through strategic investments and the upcoming implementation of new reimbursement rules for non-opioid pain management products starting in 2025. The company reaffirmed its financial guidance for the full year 2024.
Read more →PCRXPacira to Report Third Quarter 2024 Financial Results on Wednesday November 6, 2024
Pacira BioSciences, Inc. (NASDAQ:PCRX) announced it will release its third quarter financial results on November 6, 2024. After the financial results are disclosed, the company will hold a live conference call and webcast to discuss the outcomes. Pacira focuses on delivering innovative, non-opioid therapies for pain management, with several products currently approved, including EXPAREL and ZILRETTA, alongside its ongoing development of PCRX-201.
Read more →PCRXPacira BioSciences Appoints Shawn Cross as Chief Financial Officer
Pacira BioSciences has appointed Shawn Cross as its new Chief Financial Officer. Mr. Cross, who has over 25 years of experience in the biotechnology sector, will oversee all financial operations of the company. His appointment is expected to guide Pacira in long-term growth and value creation. The company is currently on strong financial footing and is generating significant cash flow from its best-in-class products.
Read more →PCRXPacira BioSciences Announces New Product-Specific J-Code for EXPAREL Effective January 1, 2025
Pacira BioSciences has announced that the Centers for Medicare and Medicaid Services (CMS) will implement a new J-code for EXPAREL, effective January 1, 2025. This new coding aims to standardize billing and reimbursement, thereby improving the reimbursement process for EXPAREL in outpatient and office-based surgical settings. The introduction of the J-code is expected to enhance access for clinicians and increase the likelihood of coverage by commercial payers. The existing C-code will be replaced, marking a significant update in how EXPAREL is billed.
Read more →PCRXPacira Announces the Presentation of 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the Knee
Pacira BioSciences, Inc. announced the upcoming presentation of 104-week safety and efficacy data for its gene therapy candidate, PCRX-201, aimed at treating moderate to severe osteoarthritis of the knee. This innovative therapy utilizes a local administration technique to deliver an anti-inflammatory protein directly to the affected joint. PCRX-201 has recently been granted Regenerative Medicine Advanced Therapy designation by the FDA, which aids in its expedited development and review process. The data will be presented at the American College of Rheumatology's ACR Convergence meeting in November 2024.
Read more →PCRXPacira BioSciences Comments on Ruling on EXPAREL Patent Litigation from U.S. District Court for the District of New Jersey
Pacira BioSciences, Inc. announced that the U.S. District Court for the District of New Jersey ruled the company's U.S. Patent No. 11,033,495 invalid. CEO Frank D. Lee expressed confidence in the company's intellectual property and indicated they are considering an appeal. Despite this setback, Pacira maintains that their EXPAREL franchise is well-protected by a strong portfolio of patents and ongoing litigation.
Read more →PCRXPacira BioSciences Reports Second Quarter 2024 Financial Results
Pacira BioSciences, Inc. reported its financial results for the second quarter of 2024, revealing total revenues of $178 million. Key products, including EXPAREL and ZILRETTA, contributed to net sales of $136.9 million and $30.7 million, respectively. The company emphasized upcoming reimbursement changes under the NOPAIN Act, aimed to enhance EXPAREL's market position starting January 2025. Although the company faced an increase in operating expenses and a decline in GAAP net income, it remains optimistic about its future revenue growth and profitability.
Read more →PCRXPacira to Report Second Quarter 2024 Financial Results on Tuesday July 30, 2024
Pacira BioSciences, Inc. announced it will report its second quarter financial results on July 30, 2024, after U.S. market close. The company will host a live conference call and webcast at 4:30 p.m. ET following the results release. Interested participants can preregister for the telephone access or listen to a live audio stream through the company's website. A replay of the conference call will be available for two weeks after the event.
Read more →PCRXPacira BioSciences to Participate in Fireside Chat at the 2024 Jefferies Global Healthcare Conference
Pacira BioSciences, Inc. (NASDAQ: PCRX) announced its participation in the 2024 Jefferies Global Healthcare Conference scheduled for June 6, 2024, in New York. The analyst-led fireside chat will focus on the company's ongoing commitment to providing non-opioid pain management solutions. Following the event, a replay of the audio webcast will be available on the company's website for two weeks. Pacira offers three commercial-stage non-opioid treatments designed to reduce opioid reliance.
Read more →PCRXPacira BioSciences, Inc. Announces Pricing of $250.0 Million Aggregate Principal Amount of 2.125% Convertible Senior Notes due 2029
Pacira BioSciences, Inc. announced the pricing of $250 million in convertible senior notes due 2029, which should strengthen its financial position. The offering aims to raise approximately $242 million net after costs, with significant proceeds allocated for repurchasing existing convertible notes and common stock. The initial purchasers of the notes have an option to acquire an additional $37.5 million, potentially boosting overall capital. This financial maneuver is part of Pacira's broader strategy to enhance its corporate stability and stock performance.
Read more →PCRXPacira BioSciences, Inc. Announces Proposed Offering of $250.0 Million Aggregate Principal Amount of Convertible Senior Notes
Pacira BioSciences, Inc. has announced its intention to offer $250 million in convertible senior notes due 2029 in a private placement aimed at qualified institutional buyers. The company plans to use part of the proceeds to repurchase outstanding 2025 Convertible Senior Notes and shares of its common stock, indicating a strategic approach to enhance its capital structure. Additionally, Pacira intends to engage in capped call transactions to mitigate potential dilution of its shares. However, the offering is contingent upon market conditions and other factors, introducing certain risks regarding completion.
Read more →PCRXPacira BioSciences Reports First Quarter 2024 Financial Results and Announces $150 Million Share Repurchase program
Pacira BioSciences has reported its financial results for the first quarter of 2024, showing revenues of $167.1 million, a slight increase from the previous year. The company announced a new share repurchase program worth $150 million, signaling confidence in its future. The launch of EXPAREL is progressing well, supported by upcoming Medicare reimbursement changes set for January 2025. Additionally, promising data for its product candidate PCRX-201 was presented at a recent congress, indicating a strong pipeline for the company.
Read more →PCRXPacira BioSciences to Participate in Fireside Chat at the 2024 RBC Capital Markets Global Healthcare Conference
Pacira BioSciences, Inc. announced its participation in the 2024 RBC Capital Markets Global Healthcare Conference, scheduled for May 14, 2024. The company aims to provide a platform for discussing its innovative non-opioid therapies, such as EXPAREL, ZILRETTA, and iovera, which are designed to enhance pain management while minimizing reliance on opioids. A live audio stream of the event will be accessible on the company's website, along with a replay for two weeks post-event.
Read more →PCRXPacira to Report First Quarter 2024 Financial Results on Tuesday May 7, 2024
Pacira BioSciences, Inc. announced plans to report its first quarter financial results on May 7, 2024, after U.S. market close. Following this announcement, the company will conduct a conference call and webcast to discuss the results. Pacira focuses on providing non-opioid pain management solutions and continues to work on interventions for conditions related to the sympathetic nervous system.
Read more →PCRXPacira BioSciences to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
Pacira BioSciences, Inc. (NASDAQ: PCRX) announced its participation in the 23rd Annual Needham Virtual Healthcare Conference scheduled for April 8, 2024. The event will feature an analyst-led fireside chat accessible via the company's investor website. Pacira aims to redefine opioid use by promoting its non-opioid treatment options, including EXPAREL®, ZILRETTA®, and iovera™. A replay of the event will be available for two weeks post-conference.
Read more →PCRXPacira BioSciences Announces PCRX-201 Granted Regenerative Medicine Advance Therapy (RMAT) Designation for the Treatment of Osteoarthritis of the Knee
Pacira BioSciences announced that its candidate PCRX-201 has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for treating osteoarthritis of the knee. This designation makes it the first gene therapy product candidate for this condition to gain RMAT status, supported by positive results from a 72-patient Phase 1 study. Preliminary data indicates that PCRX-201 is well tolerated and shows efficacy improvements at 52 weeks. Further data will be presented at OARSI 2024 and additional follow-up data is expected later this year.
Read more →PCRXPacira BioSciences to Participate in Fireside Chat at the Barclays 26th Annual Global Healthcare Conference
Pacira BioSciences, Inc. (NASDAQ: PCRX) will participate in an analyst-led fireside chat at the Barclays 26th Annual Global Healthcare Conference on March 13, 2024. The event can be accessed live and will also have a replay available for two weeks afterward. Pacira focuses on providing non-opioid treatment options and has three commercial-stage products aimed at pain management, highlighting their commitment to addressing opioid reliance.
Read more →PCRXPacira BioSciences Reports Fourth Quarter and Full-Year 2023 Financial Results
Pacira BioSciences reported impressive financial results for 2023, showcasing record revenues of $675 million, up 1% from the previous year. The company's net income reached $42 million, signifying a substantial recovery from a net loss in the prior year. Notable achievements include FDA approvals for the expansion of its EXPAREL product, which is set to enhance its market presence in non-opioid pain management. The recent appointment of CEO Frank D. Lee aims to steer the company towards sustained growth and innovation in pain management solutions.
Read more →PCRXPacira to Report 2023 Financial Results on Thursday February 29, 2024
Pacira BioSciences, Inc. has announced the upcoming release of its fourth quarter and full year financial results for 2023 on February 29, 2024. The company will host a live conference call at 8:30 a.m. ET to discuss the results, which will be available via webcast. Pacira continues its mission to provide non-opioid treatment options and has three commercial-stage products focused on pain management. This event highlights the company's continued commitment to transparency and stakeholder engagement.
Read more →PCRXPacira Announces Publication of Pivotal Study of EXPAREL as a Sciatic Nerve Block in the Popliteal Fossa for Patients After Bunionectomy
Pacira BioSciences has published findings from a pivotal Phase 3 study showing that EXPAREL, a bupivacaine liposome injectable suspension, serves as an effective sciatic nerve block for patients undergoing bunionectomy. The study demonstrated a significant reduction in pain and opioid use over 96 hours when compared to a standard treatment, bupivacaine HCl. Notably, nearly 25% of patients receiving EXPAREL required no rescue opioids, indicating a shift towards non-opioid pain management in outpatient settings. This study underlines the product's potential to enhance recovery and patient satisfaction in surgical procedures.
Read more →PCRXPacira BioSciences Awarded Brand Pharmaceuticals Agreement With Premier, Inc.
Pacira BioSciences, Inc. has entered a national group purchasing agreement with Premier, Inc. for its product EXPAREL, effective January 1, 2024. This partnership enables Premier's members to benefit from special pricing on the non-opioid injectable suspension, which aims to enhance patient care and minimize opioid reliance. The collaboration reflects both organizations' commitment to improving healthcare outcomes and providing innovative pain management solutions.
Read more →PCRXPacira Reports Preliminary Unaudited Fourth Quarter and Full-Year 2023 Revenues
Pacira BioSciences, Inc. announced its preliminary unaudited total revenue for 2023 was $675 million, up from $666.8 million in 2022. The growth was driven by an increase in net product sales, particularly from EXPAREL and ZILRETTA. Despite lower selling prices due to changes in drug pricing regulations, the company plans to invest in growth initiatives for opioid-sparing pain management solutions. Pacira expects to release complete financial results and guidance for 2024 in early 2024.
Read more →PCRXPacira BioSciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Pacira BioSciences, Inc. (NASDAQ: PCRX) is scheduled to present at the upcoming 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024. The presentation will outline the company's mission to provide effective non-opioid pain management solutions and their innovative products targeting various pain conditions. Live access to the event will be available via the company's website, with a replay offered for two weeks after the conference.
Read more →PCRXPacira Appoints Frank D. Lee as Chief Executive Officer
Pacira BioSciences has appointed Frank D. Lee as the new Chief Executive Officer, effective January 2, 2024. He is set to succeed Dave Stack, who will remain in an advisory role until August 2025. Lee brings over thirty years of experience in the pharmaceutical and biotech sectors, notably transforming Forma Therapeutics into a notable industry player. Under his leadership, Pacira aims to further enhance its non-opioid pain management offerings and capitalize on growth opportunities.
Read more →PCRXDocument FOR IMMEDIATE RELEASE NEWS RELEASE Pacira Appoints Frank D. Lee as Chief Executive Officer -- Transformational Leader Brings Three Decades of Global Experience in Pharmaceutical and Biotechnology Product Develop
Pacira BioSciences has appointed Frank D. Lee as the new CEO, effective January 2, 2024, succeeding David Stack, who will remain an advisory member. With over 30 years of experience in biotech and pharmaceuticals, Lee is expected to lead the company into its next growth phase. Additionally, Paul Hastings has been elected as Chair of the Board, ensuring a stable leadership transition. Pacira continues to focus on non-opioid pain management options, underlining its dedication to innovative health solutions.
Read more →PCRXPacira BioSciences to Participate in Fireside Chat at Two Healthcare Conferences in November
Pacira BioSciences, Inc. (NASDAQ: PCRX) will take part in two notable healthcare conferences in November. The Jefferies London Healthcare Conference is set for November 14th, followed by the 35th Annual Piper Sandler Healthcare Conference on November 28th. The company focuses on reducing opioid usage by offering innovative non-opioid pain management solutions and has several approved treatments, including EXPAREL®, ZILRETTA®, and iovera®.
Read more →PCRXPacira BioSciences Reports Third Quarter 2023 Financial Results
Pacira BioSciences reported its third quarter 2023 financial results, showing a total revenue of $163.9 million. While net product sales for EXPAREL decreased compared to the same period last year, the company remains financially strong with a net income of $10.9 million and plans for growth, including the launch of new initiatives supporting pain management education. The company has also appointed four new independent directors to enhance board diversity and governance. However, it has revised its full-year guidance for EXPAREL sales downward.
Read more →PCRXPacira BioSciences Appoints Four New Independent Directors to its Board of Directors
Pacira BioSciences has appointed four new independent directors to its Board, enhancing diversity and expertise in areas such as scientific, commercial, and financial aspects. The new members, Marcelo Bigal, Abraham Ceesay, Michael Yang, and Alethia Young, bring significant industry experience, which could positively influence the company's strategic direction in non-opioid pain management. With these appointments, Pacira aims to bolster its leadership and governance, as stated by CEO Dave Stack. This move is part of the company's broader commitment to improve its board's diversity and maintain strong corporate governance.
Read more →PCRXPacira BioSciences Announces Leadership Succession Plan David Stack to Retire as Chairman and CEO Once Successor is Appointed Board Has Initiated Search for Successor
Pacira BioSciences has announced that David Stack will retire as Chairman and CEO once a successor is appointed. The board has initiated a search for a new CEO and Stack will remain in a consulting role until August 2025 to ensure a smooth transition. During his 16-year tenure, Stack has been pivotal in transforming Pacira into a leader in non-opioid pain management solutions, emphasizing the importance of reducing opioid reliance in patient care. The company continues to focus on its mission to provide innovative pain management options.
Read more →PCRXPacira BioSciences Announces Leadership Succession Plan
Pacira BioSciences has announced the retirement of David Stack as Chairman and CEO once a successor is appointed. Stack, who has led the company for 16 years, will assist in the transition and remains committed to supporting Pacira's mission of providing non-opioid pain management solutions. The company's board has retained Klein Hersh International to conduct a comprehensive search for a new chief executive. This leadership change aims to ensure a smooth transition and continued growth for Pacira.
Read more →PCRXPacira BioSciences Announces Fireside Chat at the H.C. Wainwright 25th Annual Global Investment Conference
Pacira BioSciences, Inc. (NASDAQ: PCRX) announced its participation in the H.C. Wainwright 25th Annual Global Investment Conference with a fireside chat. The event will include a pre-recorded audio presentation accessible on the company's website beginning September 11th. Pacira is known for its focus on non-opioid pain management solutions and is expanding its portfolio with innovative treatments aimed at debilitating conditions like chronic pain and spasticity.
Read more →PCRXPacira BioSciences Reports Second Quarter 2023 Financial Results
Pacira BioSciences reported its second quarter 2023 financial results, highlighting total revenues of $169.5 million, slightly up from the previous year. The firm saw notable growth in its EXPAREL product, despite a minor decrease in net sales year over year. The company has optimism for the second half of the year due to improving market conditions and new initiatives, although it revised its sales guidance downward for EXPAREL and ZILRETTA. The firm ended the quarter with cash reserves of $220.8 million and adjusted EBITDA of $54.3 million.
Read more →PCRXPacira BioSciences to Participate in Fireside Chat at the 2023 Jefferies Healthcare Conference
Pacira BioSciences, Inc. (NASDAQ: PCRX) has announced its participation in the 2023 Jefferies Healthcare Conference, scheduled for June 7, 2023, in New York. The event will feature an analyst-led fireside chat, highlighting the company's commitment to providing innovative non-opioid treatment options and addressing pain management. Pacira markets several commercial-stage therapies aimed at reducing opioid reliance, including EXPAREL, ZILRETTA, and iovera.
Read more →PCRXPacira BioSciences to Participate in Fireside Chat at the 2023 RBC Capital Markets Global Healthcare Conference
Pacira BioSciences, Inc. will participate in the 2023 RBC Capital Markets Global Healthcare Conference, scheduled for May 16, 2023, in New York. The event will feature an analyst-led fireside chat, and live audio will be available on the company's website. Alongside this event, Pacira emphasizes its mission to provide non-opioid options for pain management, showcasing its three commercial-stage treatments. Post-conference, a replay of the webcast will be accessible for two weeks.
Read more →PCRXPacira BioSciences Reports First Quarter 2023 Financial Results
Pacira BioSciences reported its first quarter financial results for 2023, highlighting total revenues of $160.3 million and a net loss of $19.5 million. EXPAREL continues to gain traction in the elective surgery market, showing a 6% increase in average daily volumes. Additionally, the FDA's acceptance of a supplemental new drug application for EXPAREL nerve blocks represents a significant milestone. However, operating expenses have risen considerably, reflecting increased costs in other areas.
Read more →PCRXPacira BioSciences Partners with The Invited Celebrity Classic – a PGA TOUR Champions Event – to Make iovera The Official Non-Opioid Pain Management Partner
Pacira BioSciences has partnered with the Invited Celebrity Classic, a PGA TOUR Champions event, to promote its non-opioid pain management device, iovera°. The device will be showcased as the official pain management partner during the tournament and at other golf events throughout the year. The initiative aims to raise awareness among golfers and their families about the benefits of non-opioid pain relief, leveraging the presence of professional golfer Paul Goydos as a brand ambassador. This collaboration builds on previous partnerships established in 2022 to further promote non-opioid treatment options in the sports community.
Read more →PCRXPacira BioSciences, Inc. Appoints Christopher Young as Chief Manufacturing Officer
Pacira BioSciences, Inc. appointed Christopher Young as Chief Manufacturing Officer, responsible for all manufacturing activities across the company's product portfolio. Young brings extensive operations experience, having previously served as Executive Vice President of Global Operations at Akorn Inc. and Alvogen Inc. He aims to enhance production and support the company's mission of providing alternatives to opioids for better patient care.
Read more →PCRXPacira BioSciences to Participate in Fireside Chat at the 22nd Annual Needham Virtual Healthcare Conference
Pacira BioSciences announced its participation in the 22nd Annual Needham Virtual Healthcare Conference, scheduled for April 19, 2023. The event will feature an analyst-led fireside chat, and a live audio feed will be available on the company's website. Pacira is focused on advancing non-opioid treatment options, with three commercial-stage products aimed at pain management and reducing opioid dependence.
Read more →PCRXPacira BioSciences Announces Repayment and Termination of Term Loan B Facility Using Proceeds from New $150 Million 5-Year Term Loan A Facility and Existing Cash Resources - Term Loan A
Pacira BioSciences has successfully repaid and terminated its $287.5 million Term Loan B using funds from a new $150 million Term Loan A facility and existing cash. This strategic move significantly lowers the company's interest expenses and improves its debt leverage ratio. The CFO expressed confidence in the organization's ability to sustain growth and achieve adjusted EBITDA margins exceeding 50% in the future. The company ends the first quarter of 2023 with a favorable cash position, indicating stability moving forward.
Read more →PCRXPacira BioSciences Announces Repayment and Termination of Term Loan B Facility Using Proceeds from New $150 Million 5-Year Term Loan A Facility and Existing Cash Resources
Pacira BioSciences, Inc. has announced the successful repayment of its $287.5 million Term Loan B debt, utilizing proceeds from a new $150 million Term Loan A facility and existing cash resources. This transaction significantly enhances the company's debt leverage ratio and is expected to lower interest expenses by at least $15 million in 2023. The firm is confident in its future growth and has a strong cash position of around $180 million as it aims to execute its five-year plan.
Read more →PCRXPacira BioSciences Announces Departure of Yvonne Greenstreet from Board of Directors TAMPA, FL
Pacira BioSciences, Inc. announced the retirement of Yvonne Greenstreet from its Board of Directors, effective March 31, 2023, after nine years of service. Greenstreet, who is also the CEO of Alnylam Pharmaceuticals, expressed pride in her role at Pacira and confidence in the company's future in non-opioid pain management. Pacira is now in the process of identifying a new independent Board member to replace her. CEO Dave Stack thanked Greenstreet for her significant contributions to the company over the years.
Read more →PCRXPacira BioSciences Announces Yvonne Greenstreet to Retire from Board of Directors
Pacira BioSciences announced the retirement of Yvonne Greenstreet from its Board of Directors, effective March 31, 2023. Dr. Greenstreet has served as an independent director for nine years and is currently the CEO of Alnylam Pharmaceuticals. Pacira expressed gratitude for her contributions and is in the process of identifying a replacement. Dr. Greenstreet highlighted Pacira's ongoing commitment to redefining opioid use in pain management.
Read more →PCRXPacira BioSciences to Participate in Fireside Chat at the 2023 Barclays Global Healthcare Conference
Pacira BioSciences, Inc. will take part in the Barclays Global Healthcare Conference on March 15, 2023, in Miami. The company aims to highlight its commitment to offering non-opioid treatment alternatives and its innovative interventions for various conditions. Key products include EXPAREL®, ZILRETTA®, and iovera®—each addressing specific pain management requirements. Live audio of the event will be accessible on the company's investor website, with a replay available afterward.
Read more →PCRXPacira BioSciences Reports Full-Year and Fourth Quarter 2022 Financial Results
Pacira BioSciences reported strong financial results for 2022, achieving record revenues of $667 million and significant adjusted EBITDA of $213 million. The company surpassed 12 million patients treated with EXPAREL and opened a new training center in Houston. However, despite the overall success, Pacira experienced a GAAP net loss of $10.1 million in Q4 2022, alongside a 15% decline in adjusted EBITDA compared to the previous year. The firm is positioning itself for growth in 2023 with a focus on developing new indications and advancing their clinical pipeline.
Read more →PCRXPacira BioSciences Reports Preliminary Unaudited Total Revenue for 2022 of $666.8 Million
Pacira BioSciences reported preliminary unaudited total revenue of $666.8 million for 2022, marking a 23.1% increase from the previous year. Notably, the company saw growth from the net product sales of EXPAREL, ZILRETTA, and iovera, with plans to further reduce debt in 2023. Despite macroeconomic challenges, Pacira maintained a strong financial position, expecting to report positive adjusted earnings per share for the ninth consecutive year. The company aims to capitalize on its successful non-opioid pain management portfolio to support future growth.
Read more →PCRXPacira BioSciences to Present at the 41st Annual J.P. Morgan Healthcare Conference
Pacira BioSciences, Inc. (NASDAQ: PCRX) announced its participation in the 41st Annual J.P. Morgan Healthcare Conference set for January 9, 2023. The event presentation will be accessible via a live audio stream on the company's website, with a replay available for two weeks post-event. Pacira is focused on providing non-opioid treatment options to enhance pain management and target conditions related to the sympathetic nervous system.
Read more →PCRXPacira BioSciences Reports Preliminary Net Product Sales of $57.5 Million for November 2022
TAMPA, Fla., Dec. 13, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported preliminary unaudited net product sales of $57.5 million for the month of
Read more →PCRXPacira BioSciences Reports Preliminary Net Product Sales of $54.9 Million for October 2022
-- EXPAREL average daily sales for October 2022 were 106 percent of October 2021 -- TAMPA, Fla., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, toda
Read more →PCRXPacira BioSciences to Present at Two Healthcare Conferences in November
TAMPA, Fla., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the following two healthcare conferences: Jefferies London Healthcare Conference on Tuesday, November 15th at 8:00AM
Read more →PCRXPacira BioSciences Reports Third Quarter 2022 Financial Results
-- Third quarter revenue of $167 million, increased 31% over prior year -- -- Conference call today at 8:30 a.m. ET -- TAMPA, Fla., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and
Read more →PCRXPacira BioSciences Reports Preliminary Third Quarter 2022 Revenue of $167.5 Million
TAMPA, Fla., Oct. 13, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported preliminary unaudited revenues of $167.5 million for the third quarter of
Read more →PCRXPacira BioSciences Announces Positive Topline Data from Phase 3 Study of EXPAREL as a Single-dose Sciatic Nerve Block in the Popliteal Fossa for Bunionectomy
-- Second Phase 3 study achieves primary and key secondary endpoints; safely demonstrating statistically significant reductions in postsurgical pain and opioid consumption through 96 hours -- -- Company on track to submit supplemental New Drug Application in first quarter of 202
Read more →PCRXPacira BioSciences Reports Preliminary Net Product Sales of $59.1 Million for August 2022
-- EXPAREL average daily sales for August 2022 were 108 percent of August 2021 – -- More than 11 million patients have received EXPAREL since launch -- TAMPA, Fla., Sept. 13, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment
Read more →PCRXPacira BioSciences Announces Positive Topline Data from Phase 3 Study of EXPAREL as a Single-dose Femoral Nerve Block in the Adductor Canal for Total Knee Arthroplasty
TAMPA, Fla., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced positive topline results from its Phase 3 study of EXPAREL as a single-d
Read more →PCRXPacira BioSciences Reports Preliminary Net Product Sales of $50.2 Million for July 2022
-- EXPAREL average daily sales for July 2022 were 105 percent of July 2021 -- TAMPA, Fla., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today repo
Read more →PCRXPacira BioSciences Reports Second Quarter 2022 Financial Results
-- Second quarter revenue of $169 million, increased 25% over prior year, demonstrating successful integration and synergies from Flexion acquisition – -- Strong topline performance delivers solid net income and significantly positive adjusted EBITDA-- -- Conference call today
Read more →PCRXPacira BioSciences to Participate in Fireside Chat at the 2022 Wedbush PacGrow Healthcare Virtual Conference
TAMPA, Fla., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the 2022 Wedbush PacGrow Healthcare Virtual Conference at 11:30 AM ET on Wednesday, August 10, 2022. Live audio of th
Read more →PCRXPacira BioSciences Reports Preliminary Second Quarter 2022 Revenue of $169.4 Million
TAMPA, Fla., July 14, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported preliminary revenues of $169.4 million for the second quarter of 2022, com
Read more →PCRXPacira BioSciences Reports Preliminary Net Product Sales for EXPAREL and iovera of $46.0 Million for May 2022
TAMPA, Fla., June 14, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported preliminary unaudited net product sales for EXPAREL® (bupivacaine liposome
Read more →PCRXPacira BioSciences to Participate in Fireside Chat at the Jefferies Healthcare Conference
TAMPA, Fla., June 02, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the Jefferies Healthcare Conference at 9:00 AM ET on Thursday, June 9, 2022 in New York. Live audio of the event can
Read more →PCRXPacira BioSciences Reports Preliminary Net Product Sales for EXPAREL and iovera of $45.8 Million for April 2022
TAMPA, Fla., May 12, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported preliminary unaudited net product sales for EXPAREL® (bupivacaine liposome
Read more →PCRXPacira BioSciences to Present at Two Healthcare Conferences in May
TAMPA, Fla., May 10, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the following two healthcare conferences: 2022 RBC Capital Markets Global Healthcare Conference in New York, on Tuesd
Read more →PCRXPacira BioSciences Reports First Quarter 2022 Financial Results
-- First quarter revenue of $158 million, up 33% over prior year -- -- Strong topline performance delivers net income and significantly positive adjusted EBITDA -- -- Conference call today at 8:30 a.m. ET -- TAMPA, Fla., May 04, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc
Read more →PCRXPacira BioSciences Reports Preliminary Revenues of $157.4 to $158.4 Million for the First Quarter of 2022
TAMPA, Fla., April 12, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported preliminary revenues of $157.4 to $158.4 million for the first quarter of
Read more →PCRXPacira BioSciences to Participate in Fireside Chat at the 21st Annual Needham Virtual Healthcare Conference
TAMPA, Fla., April 05, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the 21st Annual Needham Virtual Healthcare Conference at 8:45 AM ET on Tuesday, April 12, 2022. Live audio of the ev
Read more →PCRXPacira BioSciences Reports Preliminary Net Product Sales for EXPAREL and iovera of $42.6 Million for February 2022
TAMPA, Fla., March 15, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported preliminary unaudited net product sales for EXPAREL® (bupivacaine liposom
Read more →PCRXPacira BioSciences to Participate in Fireside Chat at the Barclays Global Healthcare Conference
TAMPA, Fla., March 09, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the Barclays Global Healthcare Conference at 10:15 AM ET on Wednesday, March 16, 2022 in Miami. Live audio of the ev
Read more →PCRXPacira BioSciences Reports Full-Year and Fourth Quarter 2021 Financial Results
— Anesthesia-driven regional approaches drive record EXPAREL sales of $507 million in 2021 — — Full-year GAAP net income of $42 million and adjusted EBITDA of $204 million — — More than 10 million patients have received EXPAREL since launch — — Conference call today at 8:30 a.
Read more →PCRXPacira BioSciences Reports Preliminary Net Product Sales for EXPAREL and iovera of $37.3 Million for January 2022
TAMPA, Fla., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported preliminary unaudited net product sales for EXPAREL® (bupivacaine liposome
Read more →PCRXPacira BioSciences to Present at the 40th Annual J.P. Morgan Healthcare Conference
TAMPA, Fla., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will present at the 40th Annual J.P. Morgan Healthcare Conference at 3:00 PM ET on Monday, January 10, 2022. Live audio of the virtual event can be accessed by visiting
Read more →PCRXPacira BioSciences Announces Closing of $375 Million Five-Year Term Loan B
-- Provides additional operational and financial flexibility -- -- Underscores strength of forecasted earnings and operating cash flow -- TAMPA, Fla., Dec. 09, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid
Read more →PCRXPacira BioSciences Announces Closing of $375 Million Five-Year Term Loan B -- Provides additional operational and financial flexibility -- -- Underscores strength of forecasted earnings
Announces Closing of $375 Million Five-Year Term Loan B -- Provides additional operational and financial flexibility -- strength of forecasted earnings and operating cash flow -- FL, December 9, 2021 - Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commi
Read more →PCRXPacira BioSciences Reports Preliminary Net Product Sales for EXPAREL and iovera of $48.0 Million for November 2021
-- EXPAREL average daily sales for November 2021 - 122% of November 2020 – TAMPA, Fla., Dec. 07, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reporte
Read more →PCRXPacira BioSciences to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference
TAMPA, Fla., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the Piper Sandler 33rd Annual Virtual Healthcare Conference at 9:30 AM ET on Tuesday, November 30, 2021. Live audio o
Read more →PCRXPacira BioSciences Completes Acquisition of Flexion Therapeutics and Strengthens Leadership Position in Non-Opioid Pain Management
-- Adds highly complementary ZILRETTA® to Pacira commercial offering -- -- Combined portfolio offers end-to-end non-opioid solutions along the pain pathway -- TAMPA, Fla. and BURLINGTON, Mass., Nov. 19, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the indus
Read more →PCRXPacira BioSciences Completes Acquisition of Flexion Therapeutics and Strengthens Leadership Position in Non-Opioid Pain Management -- Adds highly complementary ZILRETTA to Pacira commer
Completes Acquisition of Flexion Therapeutics and Strengthens Leadership Position in Non-Opioid Pain Management complementary ZILRETTA to Pacira commercial offering -- portfolio offers end-to-end non-opioid solutions along the pain pathway -- TAMPA, FL and BURLINGTON, MA, Nove
Read more →PCRXPacira BioSciences to Present at the Jefferies London Healthcare Conference
TAMPA, Fla., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the Jefferies London Healthcare Conference at 11:20 AM GMT (6:20AM ET) on Tuesday, November 16, 2021. Live audio of t
Read more →PCRXPacira BioSciences Reports Preliminary Net Product Sales of $44.3 Million for October 2021
TAMPA, Fla., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported preliminary unaudited net product sales. EXPAREL® (bupivacaine liposome in
Read more →PCRXPacira BioSciences Reports Third Quarter 2021 Financial Results
-- Third quarter GAAP net income of $17.7 million and adjusted EBITDA of $48.1 million -- -- Conference call today at 8:30 a.m. ET -- TAMPA, Fla., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain
Read more →PCRXPacira BioSciences to Acquire Flexion Therapeutics Further Expanding Leadership Position in Non-Opioid Pain Management -- Adds highly complementary ZILRETTA to Pacira commercial offerin
BioSciences to Acquire Flexion Therapeutics Further Expanding Leadership Position in Non-Opioid Pain Management Adds highly complementary ZILRETTA to Pacira commercial offering -- Combined portfolio offers end-to-end non-opioid solutions along the pain pathway -- Further enha
Read more →PCRXPacira BioSciences to Acquire Flexion Therapeutics Further Expanding Leadership Position in Non-Opioid Pain Management
-- Adds highly complementary ZILRETTA® to Pacira commercial offering -- -- Combined portfolio offers end-to-end non-opioid solutions along the pain pathway -- -- Further enhances topline revenue growth; provides attractive potential synergies and expected to be accretive to ful
Read more →PCRXPacira BioSciences to Host Investor Day on October 15th, 2021 in Tampa, FL
TAMPA, Fla., Oct. 08, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced that it will host an Investor Day on Friday, October 15, 2021, from 8:00 A
Read more →PCRXPacira BioSciences Notified of Abbreviated New Drug Application Filing for EXPAREL
TAMPA, Fla., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, has received a Paragraph IV Certification Notice Letter advising that eVenus Pharmaceutic
Read more →PCRXPacira BioSciences Reports Preliminary Net Product Sales of $42.3 Million for August 2021
-- Expanding EXPAREL utilization continues to drive growth with average daily sales at 109% of August 2020 -- -- More than nine million patients treated with EXPAREL as of August 2021 -- PARSIPPANY, N.J., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX
Read more →PCRXPacira BioSciences to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
PARSIPPANY, N.J., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will present at the H.C. Wainwright 23rd Annual Global Investment Conference at 7:00 AM ET on Monday, September 13, 2021. Pre-recorded audio of the virtual event c
Read more →PCRXPacira BioSciences Reports Preliminary Net Product Sales of $42.1 Million for July 2021
PARSIPPANY, N.J., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported preliminary unaudited net product sales of EXPAREL® (bupivacaine lipo
Read more →PCRXPacira BioSciences to Present at the 2021 Wedbush PacGrow Healthcare Virtual Conference
PARSIPPANY, N.J., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will present at the 2021 Wedbush PacGrow Healthcare Virtual Conference at 10:20 AM ET on Tuesday, August 10, 2021. Live audio of the virtual event can be accessed b
Read more →PCRXPacira BioSciences Reports Record Revenue of $135.6 Million for the Second Quarter of 2021
-- EXPAREL average daily sales at 178% of the prior year second quarter -- -- Conference call today at 8:30 a.m. ET -- PARSIPPANY, N.J., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain managemen
Read more →PCRXPacira BioSciences Reports Preliminary Net Product Sales of $42.2 Million for May 2021
-- EXPAREL average daily sales for May 2021 were 162% of May 2020 -- -- EXPAREL momentum continues with average daily sales for May 2021 at 105% of April 2021 -- PARSIPPANY, N.J., June 08, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in
Read more →PCRXPacira BioSciences Announces Top-line Results from Phase 3 STRIDE Study Evaluating EXPAREL as a Lower Extremity Nerve Block
-- Study did not demonstrate statistical significance for primary endpoint of pain reduction from 0 to 96 hours for EXPAREL versus bupivacaine HCl -- -- EXPAREL achieves highly statistically significant reductions in pain and total opioid consumption from 24 to 96 hours versus b
Read more →PCRXPacira BioSciences to Present at the 2021 Jefferies Virtual Healthcare Conference
PARSIPPANY, N.J., May 25, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will present at the 2021 Jefferies Virtual Healthcare Conference at 9:30 AM ET on Tuesday, June 1, 2021. Live audio of the virtual event can be accessed by visiting
Read more →PCRXPacira BioSciences Announces Notice of Allowance of New Patent for EXPAREL
PARSIPPANY, N.J., May 18, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced that the United States Patent and Trademark Office (USPTO) has issued
Read more →PCRXPacira BioSciences to Present at the 2021 RBC Capital Markets Global Healthcare Conference
PARSIPPANY, N.J., May 12, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will present at the 2021 RBC Capital Markets Global Healthcare Conference at 10:20 AM ET on Tuesday, May 18, 2021. Live audio of the virtual event can be accessed by
Read more →PCRXPacira BioSciences Reports Preliminary Net Product Sales of $44.6 Million for April 2021
PARSIPPANY, N.J., May 11, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported preliminary unaudited net product sales of EXPAREL® (bupivacaine lipos
Read more →PCRXPacira BioSciences Reports First Quarter 2021 Financial Results and Business Update
-- EXPAREL average daily sales at 115% of the prior year first quarter-- -- Conference call today at 8:30 a.m. ET -- PARSIPPANY, N.J., May 04, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management a
Read more →PCRXPacira BioSciences Announces Investment in Spine BioPharma
-- Supports clinical advancement of lead candidate, Remedisc, for degenerative disc disease -- PARSIPPANY, N.J., April 20, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative healt
Read more →PCRXPacira BioSciences Seeks Court Injunction to Protect Clinical Integrity of EXPAREL in the Face of Scientifically Flawed and Misleading Information Published in Anesthesiology
PARSIPPANY, N.J., April 14, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX) today filed a lawsuit against the American Society of Anesthesiologists (ASA) and various other defendants seeking pecuniary damages and the retraction of three articles that create the f
Read more →PCRXPacira BioSciences Reports Preliminary Net Product Sales of $36.2 Million for February 2021
-- EXPAREL average daily sales at 103% of the prior year for the month of February 2021 -- PARSIPPANY, N.J., March 09, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health so
Read more →PCRXPacira BioSciences to Present at the 2021 Barclays Global Healthcare Conference
PARSIPPANY, N.J., March 03, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will present at the 2021 Barclays Global Healthcare Conference at 10:55 AM ET on Tuesday, March 9, 2021. Live audio of the virtual event can be accessed by visitin
Read more →PCRXPacira BioSciences Reports Full-Year and Fourth Quarter 2020 Financial Results
— Reports record full-year 2020 revenue of $429.6 million — — Anesthesia-driven regional approaches expanding and driving strong EXPAREL growth — — Conference call today at 8:30 a.m. ET — PARSIPPANY, N.J., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PC
Read more →PCRXPacira BioSciences Reports Preliminary Net Product Sales of $36.0 Million for January 2021
PARSIPPANY, N.J., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the leading provider of innovative non-opioid pain management options, today reported preliminary unaudited net product sales of EXPAREL® (bupivacaine liposome injectable suspension) and
Read more →PCRXPacira BioSciences Announces Equity Investment in GeneQuine Biotherapeutics
PARSIPPANY, N.J., Jan. 26, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the leading provider of innovative non-opioid pain management options, today announced that the company will lead an equity investment in GeneQuine Biotherapeutics GmbH. Under the terms o
Read more →PCRXPacira BioSciences to Present at the 39th Annual J.P. Morgan Healthcare Conference
PARSIPPANY, N.J., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will present at the 39th Annual J.P. Morgan Healthcare Conference at 7:30 AM ET on Wednesday, January 13, 2021. Live audio of the virtual event can be accessed by v
Read more →PCRXPacira BioSciences Reports Preliminary Net Product Sales of $38.9 Million for November 2020
-- EXPAREL average daily sales at 103% of the prior year for the month of November 2020 -- PARSIPPANY, N.J., Dec. 09, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the leading provider of innovative non-opioid pain management options, today reported prelimina
Read more →PCRXPacira BioSciences to Present at the 2020 Piper Sandler 32nd Annual Virtual Healthcare Conference
PARSIPPANY, N.J., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will present at the 2020 Piper Sandler 32nd Annual Virtual Healthcare Conference at 11:30 AM ET on Tuesday, December 1, 2020. Live audio of the virtual event can be
Read more →PCRXPacira BioSciences Reports Preliminary Net Product Sales of $41.7 Million for October 2020
PARSIPPANY, N.J., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the leading provider of innovative non-opioid pain management options, today reported preliminary unaudited net product sales of EXPAREL® (bupivacaine liposome injectable suspension) and
Read more →PCRXPacira BioSciences to Present at the 2020 Jefferies Virtual London Healthcare Conference
PARSIPPANY, N.J., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will present at the 2020 Jefferies Virtual London Healthcare Conference at 2:05 PM GMT (9:05 AM ET) on Tuesday, November 17, 2020. Live audio of the virtual event c
Read more →PCRXPacira BioSciences Reports Third Quarter 2020 Financial Results and Business Update
-- EXPAREL average daily sales at 110% of the prior year for the third quarter-- -- Conference call today at 8:30 a.m. ET -- PARSIPPANY, N.J., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the leading provider of innovative non-opioid pain managemen
Read more →PCRXPacira BioSciences Reports Preliminary Net Product Sales of $116.9 Million for the Third Quarter of 2020
-- EXPAREL average daily sales at 110% of the prior year for the third quarter and 110% of the prior year for the month of September -- PARSIPPANY, N.J., Oct. 07, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the leading provider of innovative non-opioid pain
Read more →PCRXPacira BioSciences to Present at the 2020 H.C. Wainwright 22nd Annual Global Investment Conference
PARSIPPANY, N.J., Sept. 11, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will present at the 2020 H.C. Wainwright 22nd Annual Global Investment Conference at 3:30 PM ET on Monday, September 14, 2020. Live audio of the virtual event can
Read more →PCRXPacira BioSciences Reports Preliminary Net Product Sales of $36.9 Million for August 2020
-- EXPAREL average daily sales at 111% of the prior year for the month of August 2020 -- PARSIPPANY, N.J., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), a leading provider of innovative non-opioid pain management options, today reported preliminary
Read more →PCRXPacira BioSciences Reports Second Quarter 2020 Financial Results and Business Update -- EXPAREL average daily sales return to year-over-year growth in month of June 2020 -- -- Conferenc
Pacira BioSciences Reports Second Quarter 2020 Financial Results and Business Update -- EXPAREL average daily sales return to year-over-year growth in month of June 2020 -- -- Conference call today at 8:30 a.m. PARSIPPANY, N.J., August 6, 2020 - Pacira BioSciences, Inc. (Na
Read more →PCRXPacira BioSciences Reports Second Quarter 2020 Financial Results and Business Update
-- EXPAREL average daily sales return to year-over-year growth in month of June 2020 -- -- Conference call today at 8:30 a.m. ET -- PARSIPPANY, N.J., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), a leading provider of innovative non-opioid pain mana
Read more →PCRXPacira BioSciences to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference
PARSIPPANY, N.J., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will present at the 2020 Wedbush PacGrow Healthcare Virtual Conference at 9:10 AM ET on Tuesday, August 11, 2020. Live audio of the virtual event can be accessed by
Read more →PCRXPacira BioSciences Announces FDA Acceptance of sNDA for EXPAREL Use in Pediatric Patients
sNDA submission based on positive Phase 3 data supporting expansion of the EXPAREL label to include use in children aged six and over PARSIPPANY, N.J., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced the U.S. Food and Drug Administration
Read more →PCRXPacira BioSciences Announces Settlement of Government Investigation
PARSIPPANY, N.J., July 28, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), a leading provider of innovative non-opioid pain management options, today announced settlement agreements that resolve all outstanding investigations and claims by the United States Depa
Read more →PCRXPacira BioSciences, Inc. Announces Pricing of $350.0 Million Aggregate Principal Amount of 0.750% Convertible Senior Notes due 2025
PARSIPPANY, N.J., July 07, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX) today announced the pricing of $350.0 million aggregate principal amount of convertible senior notes due 2025 (the “notes”) in a private placement to qualified institutional buyers pursuan
Read more →PCRXPacira BioSciences Reports Preliminary Total Revenue of $75.5 Million for Second Quarter of 2020 -- EXPAREL average daily sales return to year-over-year growth for month of June 2020 --
Pacira BioSciences Reports Preliminary Total Revenue of $75.5 Million for Second Quarter of 2020 -- EXPAREL average daily sales return to year-over-year growth for month of June 2020 -- Parsippany, NJ, July 6, 2020 - Pacira BioSciences, Inc. (Nasdaq: PCRX), a leading provide
Read more →PCRXPacira BioSciences, Inc. Announces Proposed Offering of $300.0 Million Aggregate Principal Amount of Convertible Senior Notes
Pacira BioSciences, Inc. Announces Proposed Offering of $300.0 Million Aggregate Principal Amount of Convertible Senior Notes PARSIPPANY, N.J., July 06, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX) today announced that it intends to offer, subject to market
Read more →PCRXPacira BioSciences Reports Preliminary Total Revenue of $75.5 Million for Second Quarter of 2020
PARSIPPANY, N.J., July 06, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), a leading provider of innovative non-opioid pain management options, today reported preliminary unaudited net revenue of $75.5 million for the second quarter of 2020, compared to $102.6 m
Read more →PCRXPacira BioSciences Announces Conclusion of EXPAREL Agreement with DePuy Synthes -- Orthopedic co-promotion agreement to conclude in January 2021 -- -- Significantly improves Pacira economics related to EXPAR
Pacira BioSciences Announces Conclusion of EXPAREL Agreement with DePuy Synthes -- Orthopedic co-promotion agreement to conclude in January 2021 -- -- Significantly improves Pacira economics related to EXPAREL -- N.J., July 2, 2020 - Pacira BioSciences, Inc. (Nasdaq: PCRX),
Read more →PCRXPacira BioSciences Announces Conclusion of EXPAREL Agreement with DePuy Synthes
-- Orthopedic co-promotion agreement to conclude in January 2021 -- -- Significantly improves Pacira economics related to EXPAREL -- PARSIPPANY, N.J., July 02, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), a leading provider of innovative non-opioid pain man
Read more →PCRXPacira BioSciences to Present at the 2020 BMO Prescriptions for Success Healthcare Conference
PARSIPPANY, N.J., June 16, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will present at the 2020 BMO Prescriptions for Success Healthcare Conference at 10:00 AM ET on Tuesday, June 23, 2020. Live audio of the virtual event can be access
Read more →PCRXPacira BioSciences to Present at the 2020 Jefferies Virtual Healthcare Conference
PARSIPPANY, N.J., May 27, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today reported that it will present at the 2020 Jefferies Virtual Healthcare Conference at 9:30 AM ET on Wednesday, June 3, 2020. Live audio of the event can be accessed by visiting the “Ev
Read more →PCRXPacira BioSciences to Present at the 2020 RBC Capital Markets Global Healthcare Virtual Conference
PARSIPPANY, N.J., May 13, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today reported that it will present at the 2020 RBC Capital Markets Global Healthcare Virtual Conference at 9:45 AM ET on Wednesday, May 20, 2020. Live audio of the event can be accessed by
Read more →PCRXPacira BioSciences Reports First Quarter 2020 Financial Results and Business Update
-- Total revenues increased 16 percent over prior year first quarter -- -- Conference call today at 8:30 a.m. ET -- PARSIPPANY, N.J., May 07, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), a leading provider of innovative non-opioid pain management options, t
Read more →PCRXPacira BioSciences Appoints Donald C. Manning, M.D., Ph.D. as Chief Medical Officer
-- Veteran Industry Executive and Anesthesiologist Brings Significant Clinical and Commercial Experience in Pain Management -- PARSIPPANY, N.J., May 04, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), a leading provider of innovative non-opioid pain management
Read more →PCRXPacira BioSciences to Present at the 2020 Barclays Global Healthcare Conference
PARSIPPANY, N.J., March 09, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today reported that it will present at the 2020 Barclays Global Healthcare Conference at 9:00 AM ET on Thursday, March 12, 2020. Live audio of the event can be accessed by visiting the “E
Read more →PCRXPacira BioSciences Launches National Regional Anesthesia Training Initiative with Envision Physician Services
PARSIPPANY, N.J., Jan. 21, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), a leading provider of innovative non-opioid pain management options, today announced a collaboration with Envision Physician Services to train anesthesiology clinicians on ultrasound-guid
Read more →PCRXPacira BioSciences Reports Full-Year 2019 Preliminary Revenue of $421.0 Million
PARSIPPANY, N.J., Jan. 09, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), a leading provider of innovative non-opioid pain management options, today reported preliminary unaudited net revenue of $421.0 million for 2019, a 25% increase compared with net revenue
Read more →PCRXPacira BioSciences to Present at the 38th Annual J.P. Morgan Healthcare Conference
PARSIPPANY, N.J., Jan. 08, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today reported that it will present at the 38th Annual J.P. Morgan Healthcare Conference at 9:30 AM PT (12:30 PM ET) on Wednesday, January 15, 2020. Live audio of the event can be accessed
Read more →PCRXPacira BioSciences Announces Positive Results from Phase 3 PLAY Study of EXPAREL in Pediatric Patients
PARSIPPANY, N.J., Dec. 17, 2019 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), a leading provider of innovative non-opioid pain management options, today announced positive results from its Phase 3 PLAY study of EXPAREL® (bupivacaine liposome injectable suspension)
Read more →PCRXPacira BioSciences to Present at the 31st Annual Piper Jaffray Healthcare Conference
PARSIPPANY, N.J., Nov. 26, 2019 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today reported that it will present at the 31st Annual Piper Jaffray Healthcare Conference at 9:30 AM on Tuesday, December 3, 2019. Live audio of the event can be accessed by visiting the
Read more →PCRXPacira BioSciences to Present at the Jefferies 2019 London Healthcare Conference
PARSIPPANY, N.J., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today reported that it will present at the Jefferies 2019 London Healthcare Conference at 2:40 PM GMT (9:40AM ET) on Wednesday, November 20, 2019. Live audio of the event can be accessed b
Read more →PCRXPacira BioSciences Reports Third Quarter 2019 Financial Results and Business Update
-- Total revenues increased 25 percent over prior year to $104.7 million in third quarter -- -- Conference call today at 8:30 a.m. ET -- PARSIPPANY, N.J., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), a leading provider of innovative non-opioid pain
Read more →PCRXPacira BioSciences Appoints Chris Christie to Board of Directors
PARSIPPANY, N.J., Sept. 19, 2019 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), a leading provider of innovative non-opioid pain management options, today announced the appointment of Christopher J. Christie to its board of directors. Chris Christie served as the 55
Read more →PCRXPacira BioSciences Completes Enrollment in Multicenter Registration Study of EXPAREL in Pediatric Patients
PARSIPPANY, N.J., Sept. 17, 2019 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), a leading provider of innovative non-opioid pain management options, today announced that it has reached full enrollment of its Phase 3 study of EXPAREL® (bupivacaine liposome injectable
Read more →PCRXPacira BioSciences Reports Second Quarter 2019 Financial Results and Business Update
-- Total revenues increased 22% over prior year to $102.6 million in second quarter -- -- Conference call today at 8:30 a.m. ET -- PARSIPPANY, N.J., Aug. 08, 2019 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), a leading provider of innovative non-opioid pain manag
Read more →PCRXPacira BioSciences to Present at the 2019 Wedbush Pacgrow Healthcare Conference
PARSIPPANY, N.J., Aug. 07, 2019 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today reported that it will present at the 2019 Wedbush Pacgrow Healthcare Conference at 12:45 PM ET on Tuesday, August 13, 2019. Live audio of the event can be accessed by visiting the “E
Read more →PCRXPacira BioSciences Announces Validation of EXPAREL Marketing Authorization Application from European Medicines Agency
-- Advances global expansion strategy to minimize postsurgical opioid use worldwide -- PARSIPPANY, N.J., June 25, 2019 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (“Pacira”) (NASDAQ: PCRX) today announced that the company’s Marketing Authorization Application (MAA) for EXPAREL®
Read more →PCRXPacira BioSciences Appoints Former Johnson & Johnson Executive, Max Reinhardt, as President Reinhardt brings extensive global experience leading multi-billion-dollar businesses to Pacir
Pacira BioSciences Appoints Former Johnson & Johnson Executive, Max Reinhardt, as President Reinhardt brings extensive global experience leading multi-billion-dollar businesses to Pacira PARSIPPANY, N.J., June 19, 2019 - Pacira BioSciences, Inc. (Nasdaq: PCRX) today announced t
Read more →PCRXPacira BioSciences Appoints Former Johnson & Johnson Executive, Max Reinhardt, as President
PARSIPPANY, N.J., June 19, 2019 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX) today announced the appointment of Max Reinhardt as the company’s president. Mr. Reinhardt will report to Dave Stack, chairman and chief executive officer of Pacira, and be responsible for
Read more →PCRXPacira BioSciences to Present at the Jefferies 2019 Healthcare Conference
PARSIPPANY, N.J., May 28, 2019 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today reported that it will participate in an analyst-led fireside chat at the Jefferies 2019 Healthcare Conference at 10:00 AM ET on Tuesday, June 4, 2019. Live audio of the event can be a
Read more →PCRXPacira BioSciences Reports First Quarter 2019 Revenues of $91.3 Million
-- EXPAREL® net product sales of $90.6 million up 22.4 percent over prior year first quarter -- -- MyoScience acquisition advances leadership in non-opioid pain management; corporate name change to Pacira BioSciences reflects expanding product portfolio -- -- Conference call to
Read more →PCRXPacira Completes Acquisition of MyoScience, Advancing Leadership in Non-opioid Pain Management with FDA-approved iovera System Adds highly complementary cryoanalgesia treatment to commercial offering New cor
Pacira Completes Acquisition of MyoScience, Advancing Leadership in Non-opioid Pain Management with FDA-approved iovera System Adds highly complementary cryoanalgesia treatment to commercial offering New corporate name of Pacira BioSciences reflects expanding product portfolio
Read more →PCRXPacira to Acquire MyoScience, Adding FDA-approved iovera System for Non-opioid Pain Control Novel cryoanalgesia treatment highly complementary to EXPAREL Corporate name change to Pacira BioSciences to reflec
Pacira to Acquire MyoScience, Adding FDA-approved iovera System for Non-opioid Pain Control Novel cryoanalgesia treatment highly complementary to EXPAREL Corporate name change to Pacira BioSciences to reflect expanding product portfolio Conference call today at 8:30 AM ET PAR
Read more →PCRXPacira Reports Preliminary 2018 Net EXPAREL Sales of $331 Million -- EXPAREL sales exceed upper end of guidance with expanding support from physicians, payers, and patients -- PARSIPPAN
Pacira Reports Preliminary 2018 Net EXPAREL Sales of $331 Million -- EXPAREL sales exceed upper end of guidance with expanding support from physicians, payers, and patients -- PARSIPPANY, N.J., January 3, 2019 - Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today reported prelimin
Read more →PCRXPacira Pharmaceuticals Reports Preliminary 2017 Revenues of $286.6 Million -- EXPAREL sales of $282.9 million driven by Phase 4 data, education and strategic partnerships -- PARSIPPANY,
Pacira Pharmaceuticals Reports Preliminary 2017 Revenues of $286.6 Million -- EXPAREL sales of $282.9 million driven by Phase 4 data, education and strategic partnerships -- PARSIPPANY, N.J., January 4, 2018 - Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today reported preliminar
Read more →PCRXPacira Announces Promotions of Scott Braunstein, MD, to Chief Operating Officer and Richard Scranton, MD, to Chief Scientific Officer Expanded roles reflect key accomplishments and demonstrated lead
Pacira Announces Promotions of Scott Braunstein, MD, to Chief Operating Officer and Richard Scranton, MD, to Chief Scientific Officer Expanded roles reflect key accomplishments and demonstrated leadership PARSIPPANY, N.J., December 7, 2017 Pacira Pharmaceuticals, Inc. (NASDAQ:
Read more →PCRXPacira Pharmaceuticals and TELA Bio Announce Equity Agreement Pacira to invest up to $25 million in TELA Bio to enhance commercial and clinical initiatives for distinct class of novel s
Pacira Pharmaceuticals and TELA Bio Announce Equity Agreement Pacira to invest up to $25 million in TELA Bio to enhance commercial and clinical initiatives for distinct class of novel surgical implants for soft tissue repair PARSIPPANY, NJ and MALVERN, PA, October 25, 2017 Paci
Read more →PCRXPacira Pharmaceuticals Announces Resignation of James Scibetta PARSIPPANY, N.J.
Pacira Pharmaceuticals Announces Resignation of James Scibetta PARSIPPANY, N.J., May 23, 2017 - Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that James Scibetta is resigning as the company s president to become chief executive officer of an undisclosed private ear
Read more →PCRXPacira Pharmaceuticals Announces Proposed Offering of $300 Million Aggregate Principal Amount of Convertible Senior Notes PARSIPPANY, N.J.
Pacira Pharmaceuticals Announces Proposed Offering of $300 Million Aggregate Principal Amount of Convertible Senior Notes PARSIPPANY, N.J., March 6, 2017 (GLOBE NEWSWIRE) Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that it intends to offer, subject to market and
Read more →PCRXPacira Pharmaceuticals Announces Collaboration with DePuy Synthes to Support Promotion, Education and Training of EXPAREL in Orthopedics Collaboration will focus on opportunities in joi
Pacira Pharmaceuticals Announces Collaboration with DePuy Synthes to Support Promotion, Education and Training of EXPAREL in Orthopedics Collaboration will focus on opportunities in joint reconstruction, spine, sports medicine, and trauma specialties Conference call today at 8:
Read more →PCRXPacira Pharmaceuticals, Inc. Reports Preliminary 2016 Revenues of $276.4 Million EXPAREL net product sales driven by soft tissue and orthopedic procedures PARSIPPANY, N.J.
Pacira Pharmaceuticals, Inc. Reports Preliminary 2016 Revenues of $276.4 Million EXPAREL net product sales driven by soft tissue and orthopedic procedures PARSIPPANY, N.J., January 6, 2017 - Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today reported preliminary unaudited total
Read more →PCRXPacira Pharmaceuticals Reports Estimated Full-Year 2015 Total Revenue of $249.0 Million PARSIPPANY, N.J.
Pacira Pharmaceuticals Reports Estimated Full-Year 2015 Total Revenue of $249.0 Million PARSIPPANY, N.J., January 7, 2016 Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced estimated EXPAREL (bupivacaine liposome injectable suspension) and total revenues for the fourth
Read more →PCRXPacira Pharmaceuticals Announces Favorable Resolution with U.S. Food and Drug Administration, which Reaffirms the Broad Indication for EXPAREL Terms Include Labeling Changes to Reinforce that the Use of EXPA
Pacira Pharmaceuticals Announces Favorable Resolution with U.S. Food and Drug Administration, which Reaffirms the Broad Indication for EXPAREL Terms Include Labeling Changes to Reinforce that the Use of EXPAREL is not Limited to Pivotal Trial Surgical Models, and Formal FDA Resc
Read more →PCRXPacira Pharmaceuticals Seeks Court Injunction to Defend its Rights to Share Information about EXPAREL Consistent with its FDA-Approved Indication Complaint Challenges FDA s Unlawful Efforts to Retroactively
Pacira Pharmaceuticals Seeks Court Injunction to Defend its Rights to Share Information about EXPAREL Consistent with its FDA-Approved Indication Complaint Challenges FDA s Unlawful Efforts to Retroactively Restrict the Promotion of EXPAREL Despite Its Broad Indication PARSIPPA
Read more →PCRXPacira Pharmaceuticals, Inc. Reports Second Quarter 2015 Financial Results Conference Call Today at 9 a.m.
Pacira Pharmaceuticals, Inc. Reports Second Quarter 2015 Financial Results Conference Call Today at 9 a.m. ET PARSIPPANY, N.J., July 30, 2015 Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today provided updates on EXPAREL (bupivacaine liposome injectable suspension) for postsurgi
Read more →PCRXPacira Pharmaceuticals, Inc. Reports First Quarter EXPAREL Revenues of $56.0 Million and First Quarter 2015 Financial Results EXPAREL Net Sales up 63% from Prior Year Period Conference
Pacira Pharmaceuticals, Inc. Reports First Quarter EXPAREL Revenues of $56.0 Million and First Quarter 2015 Financial Results EXPAREL Net Sales up 63% from Prior Year Period Conference Call Today at 9 a.m. ET PARSIPPANY, N.J., April 30, 2015 Pacira Pharmaceuticals, Inc. (NASDA
Read more →PCRXDRAFT RELEASE FOR IMMEDIATE RELEASE Pacira Receives Complete Response Letter from FDA for sNDA Seeking Approval of EXPAREL Use in Nerve Block to Provide Postsurgical Analgesia PARSIPPANY, N.J.
Pacira Receives Complete Response Letter from FDA for sNDA Seeking Approval of EXPAREL Use in Nerve Block to Provide Postsurgical Analgesia PARSIPPANY, N.J., March 2, 2015 Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced the receipt of a Complete Response Letter (CRL)
Read more →PCRXPacira Pharmaceuticals, Inc. Reports 2014 Financial Results Company Will Host Conference Call Today at 9 a.m.
Pacira Pharmaceuticals, Inc. Reports 2014 Financial Results Company Will Host Conference Call Today at 9 a.m. ET PARSIPPANY, N.J., February 24, 2015 Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today provided updates on the success of EXPAREL (bupivacaine liposome injectable sus
Read more →PCRXPacira Pharmaceuticals, Inc. Reports Estimated Fourth Quarter Total Revenue of $61.8 Million and Estimated Full-Year Total Revenue of $197.7 Million PARSIPPANY, N.J.
Pacira Pharmaceuticals, Inc. Reports Estimated Fourth Quarter Total Revenue of $61.8 Million and Estimated Full-Year Total Revenue of $197.7 Million PARSIPPANY, N.J., January 8, 2015 Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today provided its unaudited EXPAREL and total reve
Read more →PCRXPacira Pharmaceuticals, Inc. Reports Third Quarter EXPAREL Revenue of $50.2 Million and Third Quarter 2014 Results Company Will Host Conference Call Today at 9 a.m.
Pacira Pharmaceuticals, Inc. Reports Third Quarter EXPAREL Revenue of $50.2 Million and Third Quarter 2014 Results Company Will Host Conference Call Today at 9 a.m. ET PARSIPPANY, N.J., October 30, 2014 Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today provided updates on the
Read more →PCRXPacira Pharmaceuticals, Inc. Reports Second Quarter 2014 Results: EXPAREL Revenue up 31% Over First Quarter Company Will Host Conference Call Today at 9 a.m.
Pacira Pharmaceuticals, Inc. Reports Second Quarter 2014 Results: EXPAREL Revenue up 31% Over First Quarter Company Will Host Conference Call Today at 9 a.m. ET PARSIPPANY, N.J., July 31, 2014 Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today provided updates on the success of
Read more →PCRXNOT FOR IMMEDIATE RELEASE Pacira Pharmaceuticals, Inc. Reports First Quarter EXPAREL Revenue of $34.4 Million and First Quarter 2014 Results Company Will Host Conference Call Today at 9 a.m.
NOT FOR IMMEDIATE RELEASE Pacira Pharmaceuticals, Inc. Reports First Quarter EXPAREL Revenue of $34.4 Million and First Quarter 2014 Results Company Will Host Conference Call Today at 9 a.m. ET PARSIPPANY, N.J., May 1, 2014 Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today pro
Read more →PCRXPacira Pharmaceuticals Announces Pricing of Public Offering of Common Stock PARSIPPANY, N.J.
Pacira Pharmaceuticals Announces Pricing of Public Offering of Common Stock PARSIPPANY, N.J., April 8, 2014 (BUSINESS WIRE) Pacira Pharmaceuticals, Inc. (Nasdaq: PCRX) today announced the pricing of its previously announced public offering of 1,600,000 shares of its common stock
Read more →PCRXPacira Pharmaceuticals, Inc. Announces FDA Approval of Additional Manufacturing Suite for
Pacira Pharmaceuticals, Inc. Announces FDA Approval of Additional Manufacturing Suite for EXPAREL PARSIPPANY, N.J., March 31, 2014 Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that the U.S. Food and Drug Administration (FDA) approved an additional bulk manufacturi
Read more →PCRXPacira Pharmaceuticals, Inc. Reports 2013 Financial Results: Fourth Quarter EXPAREL Revenues Increase 53 Percent Over Third Quarter Company Will Host Conference Call Today at 9 a.m.
Pacira Pharmaceuticals, Inc. Reports 2013 Financial Results: Fourth Quarter EXPAREL Revenues Increase 53 Percent Over Third Quarter Company Will Host Conference Call Today at 9 a.m. ET PARSIPPANY, N.J., February 25, 2014 Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today provide
Read more →Competitive Position
How PCRX ranks across every disease it competes inCompetitive Position is a premium feature
See how PCRX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial